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I. INTRODUCTION 
1.1. Rheumatoid arthritis 
     
 
Rheumatoid arthritis is a chronic, systemic inflammatory disorder or a long term auto 
immune multisystem illness in which the body‟s immune system attacks the body‟s tissues and 
joints mistakenly causing an inflammatory synovitis which often progresses the destruction of 
joint ankylosis and articlular cartilage
[1]
. An autoimmune disease is a condition which arises 
from an abnormal response to our normal immune system. The immune system is a host defence 
mechanism comprising complex organisation of cells and antibodies designed normally to “seek 
and destroy” invaders of the body. The synovium(inside of joints) is a thin delicate lining serves 
as an important source of nutrients for cartilage which thickens during RA resulting in 
inflammation and pain in and around the joints. Additionally, synovial cells synthesize joint 
lubricants and helps them move smoothly such as collagens, as well as fibronectin and 
hyaluronic acid that constitute the structural framework of the synovial interstitium
[2]
. 
Figure A. Joint damage in rheumatoid arthritis 
Rheumatoid arthritis is influenced by the following factors such as gender, age, 
environmental factors and reproductive status, various studies demonstrate that genetic factors 
also play a major role on an individual‟s susceptibility to RA. It is characterized by periods of 
disease flares and remissions. Chronic inflammation of rheumatoid arthritis can cause permanent 
joint destruction and deformity. It leads to warm, swollen, painful and stiff joints which gets 
worsened following rest. Usually multiple joints of the fingers and hands, wrists, feet and knees 
typically gets affected in a symmetrical distribution (affecting both sides of the body). It may 
also affect other parts of the body and this may result in a low red blood cell count, inflammation 
around the lungs, and inflammation around the heart
[3]
. 
1.2. History 
The hallmark feature of rheumatoid arthritis (RA) is persistent symmetric polyarthritis 
(synovitis) that affects the hands and feet, although any joint lined by a synovial membrane may 
be involved. The severity of RA may fluctuate over time, but chronic RA most commonly results 
in the progressive development of various degrees of joint destruction, deformity, and a 
significant decline in functional status. Extra-articular involvement of organs such as the skin, 
heart, lungs, and eyes can also be significant. 
 
Juvenile idiopathic arthritis (JIA), sometimes referred to as juvenile rheumatoid arthritis 
(JRA), is the most common form of childhood arthritis. In most patients, the immunogenic 
associations, clinical pattern, and functional outcome of JIA are different from those of adult-
onset RA. 
Patients with RA may report difficulty performing activities of daily living (ADLs), such as 
dressing, standing, walking, personal hygiene, or use of their hands. In addition to articular 
deterioration, constitutional symptoms (eg, fatigue, malaise, morning stiffness, weight loss, and 
low-grade fever) may be present. 
 
In most patients, RA has an insidious onset. It may begin with systemic features (eg, 
fever, malaise, arthralgias, and weakness) before the appearance of overt joint inflammation and 
swelling. A small percentage (approximately 10%) of patients with this disease have an abrupt 
onset with the acute development of synovitis and extra-articular manifestations. Spontaneous 
remission is uncommon, especially after the first 3-6 months
[4].
 
 
1.3. Epidemiology 
Worldwide, the annual incidence of RA is approximately 3 cases per 10, 000 population, 
and the prevalence rate is approximately 1%, increasing with age and peaking between the ages 
of 35 and 50 years. RA affects all populations, though it is much more prevalent in some groups 
(eg, 5-6% in some Native American groups) and much less prevalent in others (eg, black persons 
from the Caribbean region). 
First-degree relatives of individuals with RA are at 2- to 3-fold higher risk for the disease. 
Disease concordance in monozygotic twins is approximately 15-20%, suggesting that nongenetic 
factors play an important role. Because the worldwide frequency of RA is relatively constant, a 
ubiquitous infectious agent has been postulated to play an etiologic role. 
Women are affected by RA approximately 3 times more often than men, but sex 
differences diminish in older age groups
[5, 6]
 .
  
In investigating whether the higher rate of RA among women could be linked to certain 
reproductive risk factors, a study from Denmark found that the rate of RA was higher in women 
who had given birth to just 1 child than in women who had delivered 2 or 3 
offspring
[7]
.
 
However, the rate was not increased in women who were nulliparous or who had a 
history of lost pregnancies
[6]
. 
Time elapsed since pregnancy is also significant. In the 1- to 5-year postpartum period, a 
decreased risk for RA has been recognized, even in those with higher-risk HLA markers.
 [8]
 
The Danish study also found a higher risk of RA among women with a history of 
preeclampsia, hyperemesis during pregnancy, or gestational hypertension.
 [6]  
In the authors view, this portion of the data suggested that a reduced immune adaptability 
to pregnancy may exist in women who are predisposed to the development of RA or that there 
may be a link between fetal microchimerism (in which fetal cells are present in the maternal 
circulation) and RA.
 [6] 
 
1.4 Classification of inflammatory arthritis 
Inflammatory arthritis is generally classified into seropositive and seronegative groups
[9]
. 
These are based on the presence of rheumatoid factor, an immunoglobulin which reacts with 
gamma globulin, in the blood of the majority of patients with seropositive disease and in a small 
minority of patients with seronegative disease. The prototype seropositive form of arthritis is 
rheumatoid arthritis. Other members include the group of conditions labelled collagen vascular 
diseases, such as systemic lupus erythematosus, scleroderma, vasculitis,  Sjogren‟s syndrome. 
Members of this group include ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and 
arthritis of inflammatory bowel disease. In addition to the presence of rheumatoid factor, there 
are extra-articular features which distinguish the seropositive from the seronegative forms of 
inflammatory arthritis. 
Seropositive is the most common diagnosis among rheumatoid arthritis patients. Being 
seropositive means that your blood tests show the presence of antibodies that can 
cause symptoms of rheumatoid arthritis. In most cases of rheumatoid arthritis diagnoses, the 
patient tests positive for rheumatoid factor and/or anti-CPP antibodies. These indicate that the 
patient is seropositive and that they possess the antibodies that cause an attack on joints and lead 
to inflammation. 
 Seronegative rheumatoid arthritis is the diagnosis of rheumatoid arthritis without the 
presence of certain antibodies in the patient‟s blood. It is one of two main types of rheumatoid 
arthritis diagnoses 
Among the seronegative inflammatory joint diseases is a group labelled 
spondyloarthritis
[10]
. This condition is characterized by inflammatory disease of the joints of the 
back, both the sacroiliac joints and the apophyseal joints of the spine.  
Seropositive rheumatoid arthritis is thought to present a more difficult and severe course 
of symptoms than seronegative patients. However, this isn‟t always the case and the treatment 
options available for seropositive patients can allow rheumatoid arthritis sufferers to still enjoy 
their quality of life. 
 Figure B. Classisfication of rheumatoid arthritis 
 
 
1.5 Different stages of Rheumatoid arthritis
[11,12]
 
 Three identified stages of rheumatoid arthritis, characterized by differing pathogenesis 
and physical changes: 
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Stage I: Early stage RA is notable by the presence of synovial membrane inflammation, which 
results in joint swelling and pain on motion. Immune cells move to the inflammation site, leading 
to high cell counts in synovial fluid; however, x-rays are typically negative, other than showing 
the possible presence of some osteoporosis and soft tissue swelling. Treatment of early-stage RA 
focuses on joint protection and inflammation control. 
Stage II: In moderate stage RA, there is T and B cell proliferation and angiogenesis in the 
synovium. Synovial tissue starts to grow into the joint cavity, across cartilage, which will be 
gradually destroyed. The joint begins to narrow because of cartilage loss. There are typically no 
joint deformities at this stage, though mobility may become limited with adjacent muscle 
atrophy. There may be mild malaise as well as the presence of nodules. Treatment goals are the 
same as stage I RA. 
Stage III: End-stage or advanced RA disease results in a cessation of inflammatory processes. 
The formation of fibrous tissue and/or bone ankylosing (fusing of bone) results in ceased joint 
function. MRI will show proliferative pannus (a membrane of granulation tissue). Patient 
symptoms are much the same as in stage III, i.e. joint pain, swelling, stiffness, weakness 
andmalaise. At this point, treatment goals focus on reduction of pain and halting additional joint 
damage. Patients with end-stage RA may undergo joint replacement surgery. 
RA progression: 
How RA progresses and expresses itself varies widely from patient to patient. This 
variability can be seen in patterns of joint involvement, as well as the degree of disease 
involvement outside of the joints, including development of rheumatoid nodules, lung 
involvement, and other RA-related complications. One patient may experience RA symptoms 
that affect only small joints, while another may have symptoms that affect only large joints. Still 
other patients will experience more generalized disease that affects a range of joints, regardless 
of size. There is also wide variation among patients in how active the disease is and how quickly 
structural damage in the joints develops. Progressive rheumatoid arthritis requires a deliberate 
treatment plan provided by a team of physicians and specialists. This plan should be tailored 
specifically to your individual symptoms and history of the disease. 
 
1.6 Signs and symptoms
[13,14]
 
The onset of rheumatoid arthritis in most patients is insidious, often beginning with fever, 
malaise, arthralgias, and muscle weakness before progressing to inflammation and swelling of 
the joints. 
RA typically manifests with the following: 
Figure C. Stages of Rheumatoid arthritis 
 Persistent symmetric polyarthritis (synovitis) of hands and feet (hallmark feature) 
 Progressive articular deterioration 
 Extra-articular involvement 
 Difficulty performing activities of daily living (ADLs) 
 Constitutional symptoms 
 
 
 
The physical examination should address the following: 
 Upper extremities (metacarpophalangeal joints, wrists, elbows, shoulders) 
 Lower extremities (ankles, feet, knees, hips) 
 Cervical spine 
 
During the physical examination, it is important to assess the following: 
 
 Stiffness 
 Tenderness 
 Pain on motion 
 Swelling 
 Deformity 
 Limitation of motion 
 Extra-articular manifestations 
 Rheumatoid nodules 
 
1.7 Pathophysiology 
The pathogenesis of RA is not completely understood. An external trigger (eg, cigarette 
smoking, infection, or trauma) that sets off an autoimmune reaction, leading to synovial 
hypertrophy and chronic joint inflammation along with the potential for extra-articular 
manifestations, is theorized to occur in genetically susceptible individuals
[15]
. 
Synovial cell hyperplasia and endothelial cell activation are early events in the pathologic 
process that progresses to uncontrolled inflammation and consequent cartilage and bone 
destruction. Genetic factors and immune system abnormalities contribute to disease propagation. 
CD4 T cells, mononuclear phagocytes, fibroblasts, osteoclasts, and neutrophils play major 
cellular roles in the pathophysiology of RA, whereas B cells produce autoantibodies (ie, 
rheumatoid factors).  
 
 
Abnormal production of numerous cytokines, chemokines, and other inflammatory 
mediators has been demonstrated in patients with RA, including the following
[16]
: 
 
 Tumor necrosis factor alpha (TNF-α) 
 Interleukin (IL)-1 
 IL-6 
 IL-8 
 Transforming growth factor beta (TGF-ß) 
 Fibroblast growth factor (FGF) 
 Platelet-derived growth factor (PDGF) 
 
Ultimately, inflammation and exuberant proliferation of the synovium (ie, pannus) leads to 
destruction of various tissues, including cartilage (see the image below), bone, tendons, 
ligaments, and blood vessels. Although the articular structures are the primary sites involved by 
RA, other tissues are also affected. 
Findings from studies of gene–environment interactions complement these observations. 
Smoking and other forms of bronchial stress (e.g., exposure to silica) increase the risk of 
rheumatoid arthritis among persons with susceptibility HLA– DR4 alleles. Moreover, smoking 
and HLA-DRB1 alleles synergistically increase one‟s risk of having ACPA. 
 Figure D. Pathophysiology of RA 
 
Disease Initiation 
The search for an elusive single trigger for RA has been ongoing for many 
years.  Multiple studies have failed to conclusively demonstrate that any organism or exposure is 
singly responsible for the disease.  However, a number of well done epidemiological studies and 
genetic studies have provided valuable information to inform our genera, albeit still incomplete, 
understanding of the dynamic process of disease initiation. 
Genetic Susceptibilities
[17]
 
In the early 1980‟s an association was described for the association of RA with class II 
major histocompatability (MHC) antigens, specifically the shared epitope found in HLA-
DR4.   Class II MHC on the surface of an antigen presenting cell interacts with a T cell receptor 
in the context of a specific antigen, usually a small peptide sequence from a protein. A sequence 
of amino acid residues with highly conserved sequence and charge characteristics within the 
hypervariable region of HLA-DR4 remains the largest genetic risk factor described for RA, 
estimated to contribute approximately 30% of the genetic risk for the disease.  It is hypothesized 
that a triggering peptide (or peptides) with a tight conformational fit for the pocket formed by 
these residues is an early event leading to the activation of T lymphocytes.   More recently, it has 
been found that modified citrullinated peptides may have significant binding specificity for 
shared epitope alleles, with some data now suggesting that citrullinated sequences from different 
proteins are associated with allelic restriction. (A more detailed discussion of citrullination is 
below). 
Other genetic susceptibilities have been described in RA, but their relative contributions 
to the disease are still not well defined.  These include peptidyl arginine deiminase-4 (PAD-4) 
which may lead to increased citrullination, PTNP22, STAT4, and CTLA4 which may be 
involved in T cell activation, TNF receptors, and others. 
That RA has a genetic component is also borne out through a number of studies of 
monozygotic (from the same embryo, thus nearly identical DNA) and dizygotic (from different 
embryos) twins. In these studies the concordance rates between twins was higher in monozygotic 
twins ranging from 15-35% compared with dizygotic twins in which the concordance was in the 
5% range.  Even the dizygotic RA prevalence was higher than the general population estimates 
of approximately 1%. It is important to emphasize however that even in twins with nearly 
identical DNA, there was far from perfect correlation of the development of RA, implicating 
many other factors related to the development of disease than genetic factors. 
 Figure E. Risk factors of RA 
Triggers of Disease  
The fact that there is not perfect genetic concordance implicates other factors in disease 
development.  A search for these elusive triggers has been largely unrevealing.  A number of 
well performed studies have demonstrated that cigarette smoking is a significant risk factor for 
the development of disease and also with disease severity.  Interestingly this relationship is 
especially strong in individuals who carry the shared epitope, and even more in patients who 
have RA auto antibodies. 
The search for bacterial or viral infections as causes of RA have often been hypothesized, and 
many patients will relate the onset of their symptoms to an antecedent infection; however, the 
recovery of organisms or their DNA from blood or joint tissue have been unfruitful in 
discovering “the” elusive infection responsible for RA. Nonetheless, the ability of an infection to 
activate a number of immunological and inflammatory pathways may “prime the pump” in 
combination with other factors. 
Perhaps the most exciting developments in the last few years in terms of RA initiation has been 
the growing research to evaluate the possible role of oral bacteria as a trigger for RA.  There has 
been a longstanding association described between periodontal disease with RA, however cause 
and effect has been far from proven.  Periodontal disease is characterized by significant 
inflammation of the gums that leads to bone destruction and collagen matrix destruction. Both 
are inflammatory diseases with many of the same mediators and pathways involved, thus this 
could simply be an association between two inflammatory processes.  However, it is now 
recognized that a specific species of bacteria,  Porphyromonas gingivalis, which colonizes 
patients with periodontal disease and marks the progression from gingivitis to more aggressive 
periodontitis has an enzyme that can cause citrullination of proteins.  With the growing 
recognition that protein citrullination is an early event leading to an immune response against 
these in RA, these data suggest that periodontal infection may precede the development of RA in 
some patients serving as a disease initiation factor. A number of groups worldwide, including our 
own, are now investigating these pathways to better understand these processes. 
Citrullination 
 The recognition of antibodies directed against citrullinated peptides in RA has been a 
major development to improve disease identification and provide prognostic 
information.  Citrulline is a post-translational modification that occurs on arginine residues 
contained within proteins and peptides. There are a number of enzymes that can cause 
citrullination to occur, present in various cell types and tissues known as peptidylarginine 
deiminases (PADs).  Citrullination is a normal process, required for normal skin formation and 
other physiologic functions.  However, in rheumatoid arthritis an autoimmune response develops 
against citrullinated peptides detected as anti-citrullinated peptide antibodies (ACPA).  One of 
tests to detect these antibodies detects anti-cyclic citrullinated peptides (anti-CCP), currently the 
most commonly used diagnostic test for them.  The presence of anti-CCP are >98% specific for 
the diagnosis of rheumatoid arthritis; however, not all patients with RA will develop anti-CCP 
antibodies
[18]
. 
Of significant importance is the recognition that these anti-CCP antibodies may be detected up to 
15 years before the onset of clinical symptoms of RA indicating a preclinical phase of disease in 
which immunologic activation is already ongoing
[19]
.  Moreover, it has recently been 
demonstrated that specific citrullinated peptide sequences bind to shared epitope alleles with 
high affinity and can lead to T cell activation. 
The mechanisms to citrullination that lead to RA remain unclear.  A polymorphism in the PAD4 
gene which may lead to increased citrullination has been described populations.  In RA patients, 
autoantibody responses also develop against the PAD4 protein, associated with a more 
aggressive disease course.  One species of oral bacteria Porphyromonas gingivalis has a PAD 
enzyme.  Given the relationships described with periodontal disease and RA, it has been 
hypothesized that this bacteria may also serve to initiate citrullination in the preclinical phases of 
RA. 
1.8 Propagation of Disease 
T cell activation 
Upon encounter with antigen in the context of MHC on an antigen presenting cell, a     T-
lymphocyte is positioned for 3 possible fates: activation, anergy / tolerance, or apoptosis 
(death).  T cell activation is only possible if the T cell receives a “second signal” through 
engaging additional cellular receptors.  One of the most important of these second signals is 
delivered through the CD28 molecule on the surface of the T cell but many other second signals 
are involved in this process of “costimulation”[20].  Upon engagement of these receptors, a T cell 
usually becomes activated.  Failure to engage the stimulatory receptors, or engagement of a 
down-regulator receptor will cause the cell to become tolerant to the antigen (eg does not 
activate when exposed to the antigen) or to undergo programmed cell death through apoptosis. 
The process of T-cell costimulation is interrupted by abatacept, a biological therapy used to treat 
RA. 
When T cells become activated, they will in turn proliferate and begin to secrete 
additional cytokines including IL-2 which furthers their proliferation, and depending on other 
exposures, cytokines such as IFN-γ, TNF, and IL-4[21].  It is the effect of these T-cell derived 
cytokines that additional cells become activated.  T cells also directly interact through surface 
receptors with other cells to generate additional activation signals. 
B Cell Activation and Autoantibodies 
B cells become activated through interactions with T cells and through soluble cytokines 
that enhance their proliferation and differentiation.  B cells express a number of receptors on 
their surfaces during their differentiation, including the molecule CD20, which is lost upon 
terminal differentiation to antibody-forming plasma cells.  B cells and plasma cells can be found 
in rheumatoid synovium sometimes as lymphoid aggregates in the subsynovium.  The effects of 
B cells extend beyond their roles in forming plasma cells including cytokine production, direct 
cellular interactions, and they themselves serve as antigen-presenting cells to T 
lymphocytes.  The role of B cells in RA has been clearly demonstrated with the efficacy of 
rituximab which eliminates circulating B cells, though with limited impact on autoantibody 
formation. 
One of the features of most autoimmune diseases is the presence of disease-specific 
autoantibodies that help to define disease phenotypes.  Antibodies are made by plasma cells, 
which represent the terminal stage of differentiation for B lymphocytes
[22]
. Rheumatoid arthritis 
is characterized by the presence of autoantibodies known as rheumatoid factors (Rf) and anti-
citrullinated peptide antibodies (ACPA, which includes the anti-cyclic citrullinated peptide 
antibody or anti-CCP).  Rheumatoid factors have been long recognized as a feature of many 
patients with RA.  These are autoantibodies in the classical sense; they are antibodies directed 
against native antibodies, most classically described as IgM antibodies that recognize the Fc 
portion of IgG molecules, but RF may also be of the IgG or IgA isotypes.  Rheumatoid factors 
are not specific for the diagnosis of RA, but are seen in many other inflammatory and 
autoimmune conditions.  These include Sjogren‟s syndrome, chronic infections including 
tuberculosis and endocarditis, hepatitis C, chronic kidney or liver disease, lymphoproliferative 
diseases including myeloma, and other conditions. While the rheumatoid factor may be seen in 
other inflammatory conditions, ACPA are highly specific for rheumatoid arthritis and define a 
more aggressive disease phenotype . 
Effector Cell Activation 
While T cells and B cells represent the immunological aspects of RA, most of the damage 
from the disease is driven through effector cells and their products including cytokines and other 
mediators.  The synovial lining in RA represents an expansion of fibroblast like cells and 
macrophages.  It is the macrophage that has been seen as one of the master orchestrators of the 
effector damage in RA.  Macrophages are rich sources and major producers of proinflammatory 
cytokines including TNF, IL-1, IL-6, IL-8, and GM-CSF
[23]
.  These cytokines further stimulate 
the macrophage, as well as other cells in the microenvironment in a including fibroblasts and 
osteoclasts, and finally at distant sites in the body through cell surface receptors including the 
hepatocyte which is responsible for the generation of acute phase response proteins (such as C-
reactive protein).  Macrophages are also producers of prostaglandins and leukotrienes, nitric 
oxide, and other pro-inflammatory mediators with local and systemic effects.  The synovial 
fibroblast, also secretes cytokines including IL-6, IL-8 and GM-CSF, and other mediators 
including destructive proteases and collagenases. 
Neutrophils are recruited in very large numbers to the rheumatoid cavity where they can 
be aspirated in the synovial fluid. The recruitment of neutrophils to the joint is likely driven by 
IL-8, leukotriene B4, and possibly localized complement activation through C5a.  Neutrophils in 
the synovial fluid are in an activated state, releasing oxygen-derived free radicals that 
depolymerize hyaluronic acid and inactivate endogenous inhibitors of proteases, thus promoting 
damage to the joint. 
Chondrocytes, like synovial fibroblasts, are activated by IL1 and TNF to secrete 
proteolytic enzymes. They may, therefore, contribute to the dissolution of their own cartilage 
matrix, thus explaining the progressive narrowing of joint spaces seen radiographically in this 
disease
[24]
. 
1.9 Inflammatory Mediators in RA 
Cytokines 
One of the most important group of mediators in RA are cytokines. The most prominent of 
these are TNF, IL-1, and IL-6.  These cytokines, released in the synovial microenvironment 
have autocrine (activating the same cell), paracrine (activating nearby cells), and endocrine 
(acting at distant sites) effects and accounting for many systemic manifestations of 
disease.  There are many shared functions of TNF, IL-1, and IL-6, and these cytokines in turn 
upregulate the expression of the others.  Among the important effects of these cytokines are
[25]
: 
 Induction of cytokine synthesis 
 Upregulation of adhesion molecules 
 Activation of osteoclasts 
 Induction of other inflammatory mediators including prostaglandins, nitric oxide, mtrix 
metalloproteinases 
 Induction of the acute phase response (e.g. C-reactive protein, increased ESR) 
 Systemic features (e.g., fatigue, fever, cachexia) 
 Activation of B cells (IL-6) 
 Other cytokines are increasingly described in RA.  These include IL-8 which is involved 
in cellular recruitment, GM-CSF involved in macrophage development, IL-15 involved 
in T cell proliferation,  IL-17 which has pleiotropic effects on multiple cell types 
including osteoblast expression of RANK leading to osteoclast activation, and IL-
23 involved in increasing TH17 cell differentiation. 
 Soluble mediators of inflammation that may diffuse in from blood and/or be formed 
locally within the joint cavity includes prostaglandins, leukotrienes, matrix and 
metalloproteinases. Prostaglandins are involved in pain senstitization localized 
inflammation, and some effects on bone,and leukotrienes play roles in vascular 
permeability and chemotaxis.  Matrix metalloproteinases (MMPs) are potent in their 
ability to enzymatically degrade  the collagen matrix of cartilage. Kinins cause release of 
prostaglandins from synovial fibroblasts, and are also potent algesic (pain-producing) 
agents. Complement may be available for interaction with immune complexes to generate 
additional chemotactic stimuli. The neuropeptide substance P is a potent vasoactive, 
proinflammatory peptide that has also been implicated in RA. 
 Figure F. Role of inflammatory mediators in RA 
 
 
 
 
 
 
1.10 Diagnosis
[26, 27, 28]
 
No test results are pathognomonic; instead, the diagnosis is made by using a combination of 
clinical, laboratory, and imaging features. Potentially useful laboratory studies in suspected  
RA include the following: 
 Erythrocyte sedimentation rate 
 C-reactive protein level 
 Complete blood count 
 Rheumatoid factor assay 
 Antinuclear antibody assay 
 Anti−cyclic citrullinated peptide and anti−mutated citrullinated vimentin assays 
 
Potentially useful imaging modalities include the following: 
 Radiography (first choice): Hands, wrists, knees, feet, elbows, shoulders, hips, cervical 
spine, and other joints as indicated 
 Magnetic resonance imaging: Primarily cervical spine 
 Ultrasonography of joints: Joints, as well as tendon sheaths, changes and degree of 
vascularization of the synovial membrane, and even erosions 
 
Joint aspiration and analysis of synovial fluid may be considered, including the following: 
 Gram stain 
 Cell count 
 Culture 
 Assessment of overall appearance 
 
1.11 Management of RA
[29, 30]
 
Nonpharmacologic, nonsurgical therapies include the following: 
 Heat and cold therapies 
 Orthotics and splints 
 Therapeutic exercise 
 Occupational therapy 
 Adaptive equipment 
 Joint-protection education 
 Energy-conservation education 
Nonbiologic disease-modifying antirheumatic drugs (DMARDS) include the following: 
 Hydroxychloroquine 
 Azathioprine 
 Sulfasalazine 
 Methotrexate 
 Leflunomide 
 Cyclosporine 
 Gold salts 
 D-penicillamine 
 Minocycline 
 
Biologic tumor necrosis factor (TNF)–inhibiting DMARDs include the following: 
 Etanercept 
 Infliximab 
 Adalimumab 
 Certolizumab 
 Golimumab 
 
Biologic non-TNF DMARDs include the following: 
 Rituximab 
 Anakinra 
 Abatacept 
 Tocilizumab 
 Sarlilumab 
 Tofacitinib 
 
 
Other drugs used therapeutically include the following: 
 Corticosteroids 
 Nonsteroidal anti-inflammatory drugs (NSAIDs) 
 Analgesics 
Surgical treatments include the following: 
 Synovectomy 
 Tenosynovectomy 
 Tendon realignment 
 Reconstructive surgery or arthroplasty 
 Arthrodesis 
 
1.12 Modes of action of Freund’s adjuvant 
Freund‟s adjuvants are irreplaceable components of induction protocols of many 
experimental animal models of autoimmune disease. Apart from the early studies done in the 
1950s and 1960s, no further direct investigation on the mode of action of these adjuvants has 
been undertaken. It is generally assumed that incomplete (IFA) and complete Freund‟s adjuvant 
(CFA) act by prolonging the lifetime of injected autoantigen, by stimulating its effective delivery 
to the immune system and by providing a complex set of signals to the innate compartment of 
the immune system, resulting in altered leukocyte proliferation and differentiation. There are 
many evidences collected from various types of studies that provide more insight in the specific 
alterations of the immune response caused by IFA and CFA. Early events include rapid uptake of 
adjuvant components by dendritic cells, enhanced phagocytosis, secretion of cytokines by 
mononuclear phagocytes, and transient activation and proliferation of CD41 lymphocytes. The 
mycobacterial components within CFA signal T lymphocytes to assume a Th1 profile so that 
strong delayed-type hypersensitivity against autoantigens develops. In the absence of 
mycobacteria, T-lymphocyte differentiation tends to assume a Th2 pro- file with strong antibody 
production only. The mycobacterial component also accounts for a morphologic and functional 
remodeling of the haemopoietic system that develops over a period of several weeks and that is 
characterized by a drastic expansion of Mac-11 immature myeloid cells. These cells have been 
found to be associated with enhanced disease in some models but with reduced disease in others. 
Thus, in experimental autoimmune diseases, CFAmediated activation of the innate immune 
compartment is important not only by regulating the early induction phase but also by providing 
a surplus of effector and regulator cells in the late phase. 
1.13 Why Methotrexate
[31, 32, 33]
? 
Methotrexate is one of the most effective and widely used medications for 
treating rheumatoid arthritis (RA) and other inflammatory types of arthritis. It‟s also one of the 
safest arthritis drugs, insist rheumatologists, despite a common misconception among many 
patients and even some primary care physicians that methotrexate is highly toxic. 
Confusion about this important medication‟s safety profile seems to exist because it is also used 
– in much higher doses – for treating some forms of cancer. Most patients who use methotrexate 
to treat their inflammatory arthritis take between 10 and 25 milligrams (mg) per week. By 
contrast, the doses used to treat leukemia and certain other types of cancer may be hundreds of 
times larger. 
That‟s not to suggest that taking methotrexate is risk-free. A 2009 review of 21 studies 
found that 73 percent of RA patients who used the medication experienced at least one side 
effect. Yet the study indicates that most of these problems were relatively minor. What‟s more, 
doctors who prescribe methotrexate for arthritis say that following a few simple steps can make 
this drug even safer to use. 
Folic Acid Is a Must 
Understanding how methotrexate works helps explain why it can cause unwanted effects. 
Researchers originally developed methotrexate in the 1940s as a cancer drug. It stops malignant 
(or cancerous) cells from rapidly multiplying and spreading by blocking their access to folate, a 
form of vitamin B, which these cells need to survive. 
Unfortunately, depleting the body of folate can affect healthy cells, too, especially those in the 
gastrointestinal (GI) tract, mouth, hair follicles and liver. 
GI problems such as nausea and vomiting are the most common side effects associated 
with methotrexate, affecting between 20and 65 percent of RA patients who take the drug. While 
hair loss is a relatively uncommon side effect in patients who take methotrexate at such doses, up 
to one third develop mouth ulcers, or sores. Many also complain of headaches, fatigue and an 
overall “blah” feeling – sometimes called “methotrexate fog” – that can occur a day after 
receiving a dose of methotrexate (which is taken in pill form or injected once a week). 
The good news: These side effects can often be short-circuited by taking a folic acid 
supplement. Folic acid is the synthetic form of folate. One study found that RA patients on 
methotrexate who took folic acid supplements lowered the risk of GI problems and mouth sores 
by 79 percent. 
A few additional steps may help prevent or relieve GI and oral problems: 
 Split the dose. Most arthritis patients take methotrexate orally, in a dose consisting of several 
pills. Some find that splitting the dose eases GI side effects; take half the pills in the morning 
and the other half 12 hours later, preferably with food. 
 Ask about medication. For very severe stomach queasiness, your doctor can prescribe an 
anti-nausea drug such as ondansetron (Zofran). 
 Swap your pills. When nothing else helps, switching from oral methotrexate to the injectable 
version can eliminate GI distress. 
 Try a rinse. To relieve painful mouth sores, a salt-water rinse or special mouthwash 
containing lidocaine (a pain reliever) may help. 
Protecting the Liver 
Since methotrexate blocks folate, taking folic acid – the manmade version of the vitamin 
– might seem like it would be counterproductive. However, methotrexate appears to relieve pain 
and other RA symptoms through actions that are largely unrelated to folate. Investigators 
discovered that methotrexate causes cells to release a molecule called adenosine, which blocks 
other chemicals that promote inflammation. 
Fighting inflammation helps relieve painful, swollen joints. But it is also noted that 
adenosine causes fibrosis, or buildup of scar tissue, in the liver; over time, that could result in 
liver disease. It is important to note that alcohol also releases adenosine in the liver. In rare cases, 
methotrexate users may develop fibrosis and inflammation in the lungs, though this is unlikely to 
be related to adenosine release. 
Regular blood tests are also necessary to detect signs of other problems that can arise in 
methotrexate users, including a drop in white blood cells, which normally guard against 
infections. Also, some people experience a dip in production of blood platelets, which could 
cause abnormal bleeding. However, these changes in the blood often go away if you stop taking 
the drug temporarily (which should only be done under a doctor‟s supervision). 
1.14 Etiology 
The cause of RA is unknown. Genetic, environmental, hormonal, immunologic, and 
infectious factors may play significant roles. Socioeconomic, psychological, and lifestyle factors 
(eg, tobacco use, the main environmental risk
 [34] 
) may influence disease development and 
outcome. 
Genetic factors 
Genetic factors account for 50% of the risk for developing RA. 
 
About 60% of RA 
patients in the United States carry a shared epitope of the human leukocyte antigen (HLA)-DR4 
cluster, which constitutes one of the peptide-binding sites of certain HLA-DR molecules 
associated with RA (eg, HLA-DR beta *0401, 0404, or 0405). HLA-DR1 (HLA-DR beta *0101) 
also carries this shared epitope and confers risk, particularly in certain southern European areas. 
Other HLA-DR4 molecules (eg, HLA-DR beta *0402) lack this epitope and do not confer this 
risk. 
Genes other than those of the major histocompatibility complex (MHC) are also 
involved. Results from sequencing genes of families with RA suggest the presence of several 
resistance and susceptibility genes, including PTPN22 and TRAF5.
 [35, 36]
 
Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA), is a 
heterogeneous group of diseases that differs markedly from adult RA. 
 JIA is known to have genetically complex traits in which multiple genes are important 
for disease onset and manifestations, and it is characterized by arthritis that begins before the age 
of 16 years, persists for more than 6 weeks, and is of unknown origin.
[37] 
The IL2RA/CD25 gene 
has been implicated as a JIA susceptibility locus, as has the VTCN1 gene.
[38]
 
Some investigators suggest that the future of treatment and understanding of RA may be 
based on imprinting and epigenetics. RA is significantly more prevalent in women than in 
men,
[39,40] 
which suggests that genomic imprinting from parents participates in its 
expression.
[41,42] 
Imprinting is characterized by differential methylation of chromosomes by the 
parent of origin, resulting in differential expression of maternal over paternal genes.
 [43]
 
Epigenetics is the change in DNA expression that is due to environmentally induced 
methylation and not to a change in DNA structure. Clearly, the research focus will be on 
environmental factors in combination with immune genetics. 
Infectious agents 
For many decades, numerous infectious agents have been suggested as potential causes of 
RA, including Mycoplasma organisms, Epstein-Barr virus (EBV), and rubella virus. This 
suggestion is indirectly supported by the following evidence: 
 Occasional reports of flulike disorders preceding the start of arthritis 
 The inducibility of arthritis in experimental animals with different bacteria or bacterial 
products (eg, streptococcal cell walls) 
 The presence of bacterial products, including bacterial RNA, in patients‟ joints 
 The disease-modifying activity of several agents that have antimicrobial effects (eg, gold 
salts, antimalarial agents, minocycline) 
 
Emerging evidence also points to an association between RA and periodontopathic 
bacteria. For example, the synovial fluid of RA patients has been found to contain high levels of 
antibodies to anaerobic bacteria that commonly cause periodontal infection, including 
Porphyromonas gingivalis.
[44,45] 
Hormonal factors 
Sex hormones may play a role in RA, as evidenced by the disproportionate number of 
females with this disease, its amelioration during pregnancy, its recurrence in the early 
postpartum period, and its reduced incidence in women using oral contraceptives. Hyper 
prolactinemia may be a risk factor for RA.
[46] 
 
Immunologic factors 
All of the major immunologic elements play fundamental roles in initiating, propagating, 
and maintaining the autoimmune process of RA. The exact orchestration of the cellular and 
cytokine events that lead to pathologic consequences (eg, synovial proliferation and subsequent 
joint destruction) is complex, involving T and B cells, antigen-presenting cells (eg, B cells, 
macrophages, and dendritic cells), and various cytokines. Aberrant production and regulation of 
both proinflammatory and anti-inflammatory cytokines and cytokine pathways are found in RA. 
T cells are assumed to play a pivotal role in the initiation of RA, and the key player in 
this respect is assumed to be the T helper 1 (Th1) CD4 cells. (Th1 cells produce IL-2 and 
interferon [IFN] gamma.) These cells may subsequently activate macrophages and other cell 
populations, including synovial fibroblasts. Macrophages and synovial fibroblasts are the main 
producers of TNF-a and IL-1. Experimental models suggest that synovial macrophages and 
fibroblasts may become autonomous and thus lose responsiveness to T-cell activities in the 
course of RA. 
B cells are important in the pathologic process and may serve as antigen-presenting cells. 
B cells also produce numerous autoantibodies (eg, RF and ACPA) and secrete cytokines. 
The hyperactive and hyperplastic synovial membrane is ultimately transformed into 
pannus tissue and invades cartilage and bone, with the latter being degraded by activated 
osteoclasts. The major difference between RA and other forms of inflammatory arthritis, such 
as psoriatic arthritis, lies not in their respective cytokine patterns but, rather, in the highly 
destructive potential of the RA synovial membrane and in the local and systemic autoimmunity. 
Whether these 2 events are linked is unclear; however, the autoimmune response 
conceivably leads to the formation of immune complexes that activate the inflammatory process 
to a much higher degree than normal. This theory is supported by the much worse prognosis of 
RA among patients with positive RF results. 
 
 
 
1.15 Articular and systemic effects of RA 
Articular Manifestations 
Inflammation and subsequent destruction of synovial joints is the hallmark of RA. Why 
the immune system is lured to attack and destroy still remains unknown, but great strides have 
been made in understanding how. Inflammation of the synovial tissue involves interactions 
between macrophages, T and B lymphocytes, synovial fibroblasts, and other cells of the inflamed 
synovium such as mast cells, dendritic cells and plasma cells. Neutrophils are rare in RA 
synovial tissue but abundant in RA synovial fluid. These cell-cell interactions occur both through 
direct cell-cell contact, as well as through the effects of secreted mediators. Proinflammatory 
cytokines, such as TNFα, IL-1 and IL-6, orchestrate synovial inflammation and stimulate 
cartilage degradation. This occurs through formation of a distinct tissue termed synovial pannus 
which invades cartilage with the assistance of proteolytic enzymes. Concurrently osteoclasts, 
which can form within the pannus through fusion of monocytic precursors, invade bone and 
cause periarticular erosions. 
RA can involve most synovial joints, but rarely the DIPs or the thoracic, lumbar and 
sacral spine. The most commonly affected joints include the MCP and PIP joints of the hands, 
wrists and MTP joints of the feet. Joint destruction begins early in the disease with erosive 
changes often seen after only six months. The clinical exam can disclose synovial thickening and 
swelling, indicators of joint inflammation. At the time of presentation, nearly 70% of radiographs 
can be normal, but MRI and ultrasound with power Doppler have higher sensitivity to detect 
smaller erosions and synovial inflammation, and may reveal changes even when X-rays are 
normal
[47]
. If RA is left untreated, progression to joint destruction, subluxation and severe 
disability are the likely outcomes. 
Inflammation of tendon sheaths also contributes to RA pathology. Tenosynovitis of the 
flexor tendons can lead to trigger finger, and weakening of the extensor tendons of the hands 
from chronic inflammation can lead to tendon ruptures. Damage to supporting and tracking 
structures associated with tendons of the hand contribute to the formation of boutonniere and 
swan-neck deformities. Carpal tunnel syndrome secondary to median nerve compression by 
surrounding inflammation is also a common complication in RA patients. 
Bone Manifestations[48] 
The bones of RA patients are affected in both a local and systemic manner. At a local 
level, factors that stimulate osteoclasts resulting in increased bone resorption are released from 
inflammatory and fibroblastic pannus cells. Additionally, inflammatory cytokines prevent a 
compensatory increase in the rate of periarticular bone formation, resulting in net bone loss. This 
inhibition of osteoblastic activity is via a combination of impaired mineralization and impaired 
osteoblast differentiation. These processes combine to result in both periarticular osteopenia, one 
of the first radiographic signs of RA, and periarticular erosions, the hallmark of RA joint 
destruction. The use of disease modifying agents to induce clinical remission allows for 
restoration of normal function of osteoclasts and osteoblasts and may result in repair of erosive 
damage. 
Bony changes in RA patients are not only seen in a periarticular distribution. RA is a 
known risk factor for osteoporosis, with up to 30% of patients affected by some estimates
[49]
. 
Most studies agree that, unlike postmenopausal osteoporosis, the risk of osteoporosis in RA 
patients is greater at the femoral neck than in the spine, but both areas can be involved. Disease 
duration and severity, sex, body mass and the use of corticosteroids all influence the risk of 
osteoporosis in RA patients. 
An additional consideration is that many RA patients are on bisphosphonate therapy for 
osteoporosis or prevention of glucocorticoid-mediated bone loss. Research into the impact of 
bisphosphonate use in patients undergoing surgical procedures is ongoing. Osteonecrosis of the 
jaw in patients on bisphosphonates undergoing dental surgery has been a specific concern, but 
the consequences of manipulation of the peripheral skeleton in patients on these medications are 
still incompletely understood. Most research into this topic is in animal systems, and there are 
suggestions that while bone healing is not prevented, there are differences in bone quality after 
bisphosphonate exposure. 
Airway Manifestations[50] 
The presence of airway disease in RA is estimated to affect 20–30% of patients. 
Manifestations can include cricoarytenoid arthritis, pulmonary fibrosis and small airway 
disease, typically seen as bronchiolitis obliterans on histopathology, with obstructive 
abnormalities on lung function testing. Lung disease is more frequent in RA patients who 
are male, seropositive, smoke, and have longstanding disease. Some types of RA-
associated lung disease are steroid responsive, but some patients have a progressive 
course leading to end-stage fibrosis and death
3
. In addition to lung disease secondary to 
RA, patients are also at risk for pulmonary toxicities from RA-related medications, 
including methotrexate, leflunomide and even anti-TNF medications. 
Cardiovascular Manifestations 
RA patients have a 40% increased risk of mortality as compared to the general population 
after 20 years of disease. This increased risk of mortality is primarily attributed to an increased 
incidence of cardiovascular disease. A recent cohort study has suggested that the risk of 
cardiovascular events in RA patients is 2-fold higher than the general population, equivalent to 
the risk of patients with diabetes. The propensity for vascular changes is found even in newly 
diagnosed patients, indicating that common mechanisms may exist linking synovitis resulting in 
joint destruction with endothelial dysfunction resulting in atherosclerosis. 
The risk of cardiovascular disease and death increases with more severe disease and 
elevated inflammatory markers. Despite improved treatments for the symptoms of RA, the 
mortality risk has not improved over the past two decades. Whether this continued risk of death 
reflects an inability to control cardiovascular risk factors with immunomodulatory treatment or a 
lack of long-term follow up in patients treated with newer medications remains to be determined. 
Additionally, the optimal management of traditional cardiovascular risk factors, such as elevated 
cholesterol, has not been determined for RA. 
1.16 COMPLICATIONS OF MEDICAL TREATMENT OF RA
 
[51,52]
RA itself confers an elevated risk of infection, and DMARD and biologic therapies 
suppress the immune system through various targets, also increasing this risk. Bacterial 
infections, particularly pneumonia and soft-tissue infections,are increased with the use of 
methotrexate, and this is increased 2–4-fold with the addition of an anti-TNF medication. Similar 
infectious risks have been found with other biologic DMARDs as well.  A significant risk of 
reactivation of tuberculosis has also been noted with anti-TNF medication. Thus, screening for 
TB exposure and treatment of latent TB prior to initiation of anti-TNF agents is recommended. 
Similar precautions are in place for other RA biologics, although the actual risk of TB due to 
these medications is less well understood. 
TNF blockers also increase the risk for severe and systemic fungal infections such as 
histoplasmosis and coccidioidomycosis, which may be a significant issue in specific geographic 
locales.  
An increased risk of viral infections with traditional or biologic DMARDs, including 
varicella-zoster virus, Epstein-Barr virus and cytomegalovirus has been documented.  
Hepatitis B and C reactivation have also occurred with biologic DMARDs, so screening 
prior to treatment and vaccination when possible is recommended. Progressive multifocal 
leukoencephalopathy, an infection caused by reactivation of the JC virus, has also been reported 
in RA patients treated with Rituximab. 
Immunosuppression also can lead to a theoretical risk of malignancy, as tumor 
surveillance by the immune system may be affected. Since RA patients have an increased risk of 
lymphoma secondary to the disease itself, the extent of the increased risk of developing a cancer 
such as lymphoma while taking immunosuppressive medications remains debatable.  
A recent analysis of a German RA registry did not find an increased risk of malignancy, 
either hematologic or solid tumor, with the use of anti-TNF agents or anakinra,however, this 
included only four years of exposure data. Contrarily, an analysis of French patients on anti-TNF 
medications has shown an increased incidence of lymphoma in patients on adalimumab or 
infliximab.   
The coexistence of other autoimmune diseases, such as Sjögren‟s syndrome, may also 
increase the likelihood of developing lymphoma, thus making it more difficult to determine the 
contribution from immunosuppressive medications. 
 Of all the non-joint-related complications of RA, cardiovascular disease is the most 
serious. It is the leading cause of death in both men and women in the U.S., and people with RA 
have twice the risk of most cardiovascular-related problems compared with the general 
population, including heart attack, strokes and atherosclerosis – hardening of the arteries caused 
by the build-up of plaque on the inner walls of the blood vessels. The risk of heart failure is also 
increased. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. LITERATURE REVIEW 
1. Preliminary evaluation of anti-inflammatory and anti-arthritic activity of S.lappa, 
A.speclosa and A.aspera. 
 
Gokhale AB et. al., 2002 assessed anti-inflammatory and anti-arthritic activity of 
Saussurea  lappa, Argyreia speciosa and Achyranthes aspera.The ethanolic extracts of the plants 
of the doses of 50, 100 and 200 mg/kg p.o. were screened for their effect on acute and chronic 
inflammation induced in mice and rats.S.lappa and A. speciosa were found to inhibit paw odema 
induced by carrageenan and Freund‟s complete adjuvant and to prevent accumulation of 
inflammatory cells in carrageenan –induced peritonitis at doses of 50-200 mg/kg.A. aspera 
inhibited inflammatory responses at doses of 100-200 mg/kg.The studies reveal that the ethanolic 
extracts of S.lappa, A. speciosa and A. aspera posses anti-inflammatory and anti-arthritic activity 
and support the rationale behind the traditional use of these plants in inflammatory conditions. 
 
2. Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus 
Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis 
 
Ramadan G et.al, 2011 evaluated and compared anti-inflammatory and anti-oxidant 
properties of curcuma longa and zinger offficinale rhizomes in adjuvant induced arthritic 
rats.Both plants (at dose 200 mg/kg body weight) significantly suppressed the incidence and 
severity of arthritis by increasing/decreasing the production of anti-inflammatory/pro-
inflammatory cytokines, respectively, and activating the anti-oxidant defense system.The anti-
arthritic activity of turmeric exceeded that of ginger and indomethacin, especially when the 
treatment started from the day of arthritis induction.The percentage of disease recovery was 4.6-
8.3% and 10.2% more in turmeric compared with ginger and indomethacin (p<0.5), respectively. 
 
 
 
3. Evaluation of anti-nociceptive and anti-inflammatory effectof the crude extract of I. 
pes-caprae in mice 
 
Souza et al., 2000 showed pronounce anti-nociceptive action of the hydro-alcoholic extract of 
I. pescaprae against two classical models of pain, neurogenic and inflammatory and support at 
least the traditional use of this plant for the treatment of dolorous processes.  
 
4. Anti-Arthritic Potential of the Plant Justicia Gendarussa Burm F 
 
Jaijesh Paval et.al, 2009 evaluated the anti-arthritic potential of the alcoholic extract of the 
plant Justicia gendarussa using the Freund‟s adjuvant-induced and collagen-induced arthritic rat 
models.The rats were treated with the ethanolic extract of Justicia gendarussa and with standard 
aspirin and showed significant arthritic activity similar to that of aspirin. The result obtained 
suggests that the alcoholic extract of Justicia gendarussa exhibits significant anti-arthritic 
potential.  
 
5. Anti-Arthritic Activity of Premna serratifolia Linn., Wood against Adjuvant 
Induced Arthritis 
 
Rajendran R et.al, 2010 evaluated, anti-arthritic activity of ethanol extract of Premna 
serratifolia Linn. in Freund‟s adjuvant induced arthritis model.Loss in body weight during 
arthritis condition was corrected on treatment with ethanol extract and standard drug 
indomethacin.Biochemical parameters such as hemoglobin content, total WBC, RBC, 
erythrocyte and sedimentation rate were also estimated.The ethanol extract at the dose of 300 
mg/kg body weight inhibited the rat paw edema by 68.32% which is comparable with standard 
drug indomethacin 74.87% inhibition of rat paw edema after 21 days.The ethanol extract of 
Premna serratifolia Linn wood possess a significant anti-arthriticactivity against 
adjuvantinducedarthritis andjustifying its therapeutic role in arthritic condition. 
 
6. Evaluation of ant-arthritic activity potential of the methanolic extract of the aerial 
parts of costus speciosus 
Shruti Srinivastava et al., 2012 assessed the anti-arthritic potential of Costus speciosus in 
Freund‟s adjuvant animals. The methanolic extract of CS in doses of 400 and 800 mg/kg showed 
75.50% and 68.33% protection against increase in paw edema, respectively. CS showed dose-
dependent action in all the experimental models. 
 
7. Anti per oxidative effect of Withania somnifera root powder on liver lipid per 
oxidation and anti oxidant status in adjuvant induced arthritic rats 
M.Rasool et.al.,2008 evaluated anti per oxidative effect of Withania somnifera root powder 
on liver lipid per oxidation and anti-oxidant status in adjuvant induced arthritic rats.Withania 
somnifera root powder (1000mg/kg) and indomethacin (3mg/kg) were orally administered for 8 
days beginning 11 days after adjuvant injection.Results showed a significant decrease in the level 
of lipid peroxides, constituents with the increased enzymatic anti oxidants and depleted non 
enzymatic anti oxidant status in arthritic animals. 
 8. Evaluation of protective efficacy of Spirulina platensis against collagen-induced 
arthritis in rats. 
Narendra Kumar et al., 2009 evaluated the protective efficacy ofSpirulina platensis against 
collagen induced arthritis (CIA) in female wistar rats based on the changes in paw thickness, 
altered serum albumin, cholesterol, lipid per oxidation, alkaline phosphates and acid phosphatase 
activities and histology of paw joints.CIA rats were orally treated with 200 and 400 mg/kg per 
oral of S. platensis from 0 to 45 day. S.Platensis at 400 mg/kg per oral significantly elevates 
serum albumin and decreases the serum cholesterol, alkaline phosphatase and acid phosphatase 
activities, lipid per oxidation, paw thickness as well as normalize the joint histopathology of CIA 
rats.S.platensis at (400 mg/kg) significantly reduced the arthritic symptoms in treatment groups 
and this indicates that S.platensis has promising protective efficacy against CIA rats. 
 
9. Anti rheumatoid activity of aqueous extract of piper longum on freund’s adjuvant-
induced arthritis in rats 
Yende et al., 2010 studied anti arthritic activity of aqueous extract of the fruits of the plant 
piper longum in Freund‟s adjuvant Induced Arthritis Rats with the dose of 200 and 400 mg/kg 
p.o.The administration of extract reported significant reduction in paw swelling on 4
th
, 8
th
, 14
th
 
and 21
st
 day after sub-plantar administration of Complete Freund‟s adjuvant.The paw swelling 
was measured as a volume displacement using digital plethysmometer.Furthermore, these results 
supported by radiographic analysis of affected knees of rats.From the result observed in the 
present investigation, it may be concluded that the aqueous extract of P.longum possesses 
potentially useful anti-arthritic activity in Complete Freund‟s Adjuvant model. 
 
10. Anti-arthritic activity of roots of Hemidesmus indicus R.Br.(Anantmul) in rats 
Alka metha et.al, 2012 evaluated the protective effects of hydro alcoholic and its fractions from 
roots of Hemidesmus indicus in complete Freund‟s adjuvant induced arthritis.Rats treated with 
hydro alcoholic extract (450 mg/kg p.o.) ethyl acetate (75 mg/kg p.o) chloroform (60 mg/kg.p.o) 
and residual fractions (270 mg/kg.p.o) showed significant decrease in physical and biochemical 
parameters compared with arthritic model rats.Hydro alcoholic extract and its ethyl acetate 
fraction of Hemidesmus indicus showed significantly higher anti-arthritic activity than 
chloroform and residual fraction.Histopathological analysis demonstrated that both of hydro 
alcoholic extract and its ethyl acetate fraction and comparable anti-arthritic activity with 
methotrexate.The present study suggested that Hemidesmus indicus has protective activity 
against arthritis and the activity might be attributed to presence of terpenoid in hydro alcoholic 
extract, as well as in ethyl acetate fraction. 
 
11. Protective effect of latex of Calotropis procera in Freund’s Complete Adjuvant 
induced monoarthritis 
Kumar VI et al, 2009 proved the protective effect of latex of Calotropis procera in Freund‟s 
Complete Adjuvant(FCA) induced monoarticular arthritis in rats. The effects of dried latex and 
its methanol extract following oral administration was evaluated on joint inflammation, 
hyperalgesia, locomotor function and histology at the time of peak inflammation. The results 
obtained suggested that the latex of C.procera has the potential to be used as an anti-arthritic 
agent. 
 
12. Anti-Rheumatic and Antioxidant activity of the extract of Stem bark of Ficus 
bengalensis 
Manocha N et al., 2011 assessed the analgesic, anti rheumatic and anti oxidant activity of the 
methaolic extract of the bark of Ficus bengalensis(MFB) at doses of 100, 200 and 300 mg/kg(i.p) 
using the Freund‟s Complete Adjuvant induced arthritis model, the Formalin induced arthritis 
model and the Agar induced arthritis model . The extract produced marked inhibitory effect on 
edema especially on secondary immunological arthritis and caused graded inhibition of both 
phases of Formalin-induced pain. The present study validates the traditional use, demonstrating 
that the methanolic extract of the bark of this plant possesses dose-dependent anti-rheumatic 
activity in all the models with a possibility of acting through centrally and peripherally mediated 
activities. 
 
 
 
  
III. SCOPE AND PLAN OF WORK 
3.1 SCOPE OF WORK 
Rheumatoid arthritis is not a single disease where as it is an auto immune disease which 
affects the whole body system. Hence it is also known as a systemic disease where the joints are 
usually affected symmetrically. There are more than 100 types of arthritis and related conditions 
where the body‟s own immune system attacks the synovial membrane of the joint and causes 
synovitis. This results to various painful symptoms such as swelling and stiffness of joint and if 
left untreated the joint might permanently damage, resulting in deformity. Hence the goal of the 
treatment are as follows: 
 Rectify the underlying cause of the disease i.e. to rectify or modify the deviated immune 
system of its abnormal reaction towards the healthy joint tissues to normal protective 
action. 
 Management of symptoms: Homeopathy treatment targets the deviated immune system, 
which behaves in an abnormal way to healthy joint tissues and converts it to a healthy 
functioning immune system.  
 Technology: Activated T-cells in the body are involved in the autoimmune response that 
leads to the joint inflammation and destruction often associated with RA. Abatacept 
(Bristol-Myers Squibb Pharmaceuticals Ltd) is a soluble fusion protein and is the first in 
a new class of agents called selective T-cell costimulation modulators. It acts by blocking 
one of the two signals needed for optimal T-cell activation, thereby interrupting the 
inflammatory process. Abatacept is administered via intravenous infusion. 
 Abatacept is licensed in the US for the treatment of patients with moderately to 
severely active rheumatoid arthritis who have had an inadequate response to one or more 
DMARDs. It may be used as monotherapy or concurrently with other DMARDs except 
for TNF alpha inhibitors. Abatacept is not licensed in the UK, but an application for 
marketing authorisation has been submitted to the EMEA.  
 
3.2 PLAN OF WORK 
  
 
REVIEW OF 
LITERATURE
• Critical part of thesis writing.
• Compile, Classify, analyze and compare articles and 
evaluation needs to be done
PLANT SELECTION
• Choose the suitable plant for work with effective 
therapeutic claims
COLLECTION AND 
AUTHENTICATION
• Collect the plant material from reliable source
• Quality assurance process
EXTRACTION
• To defat the raw material and to extract the whole 
plant of Mimosa pudica Linn. using ethanol to 
isolate the active constituents
PRELIMINARY 
PHYTO-
CHEMICAL 
STUDY
• To identify and evaluate the active phytochemical 
constituents of the whole plant of Mimosa pudica 
Linn by chemical tests
INVITRO
METHODS
• To determine the anti arthritic property of the whole 
plant of Mimosa pudica by conducting various in 
vitro tests
  
 
 
ANIMAL 
MODELS
• Choose the right animal to explore the 
pharmacological activity of the plant effectively
PRELIMINARY 
PHYTO-
CHEMICAL 
STUDY
• To identify and evaluate the active phytochemical 
constituents of the whole plant of Mimosa pudica 
Linn by chemical tests
ACUTE ORAL 
TOXICITY
• Assess the safety profile of Mimosa pudica to assess 
the toxicity which depends on the mortality and 
morbidity status of the animals(OECD 423)
INVIVO
SCREENING
• Investigate the anti-arthritic activity of the whole 
plant in Complete Freund's Adjuvant induced 
arthritic rats using various parameters
HISTOPATHOL
OGY STUDY
• Determine the effect of the plant or microscopic 
examination of a biopsy or surgical specimen
BIOCHEMICAL 
PARAMETERS
• Analyze the blood or serum of the dissected animals 
for biochemistry analysis  
IV. MATERIALS AND METHODS 
 4.1 Collection of plant materials: 
 
Figure G. Fresh herbs of Mimosa pudica Linn. 
 
The plant Mimosa pudicaLinn.grows nearly throughout the tropical and sub-tropical parts 
of India. It is common in waste ground, particularly where the climate is moist and warm. 
The plant is considered invasive in tropical climates. 
 Temperature. Sensitive plant will grow indoors next to a sunny window with some direct 
sunlight. 
 Soil. Sensitive plant should be planted in well-draining loamy soil enhanced with peat moss to 
improve drainage. 
 
 Figure H. Air-dried Mimosa pudica Linn. 
Fresh and healthy plant materials were collected from Nellore district, Andhra Pradesh. It 
was identified and authenticated by Prof.P Jayaraman, Ph.D, Director, Institute of herbal botany, 
Plant anatomy and research centre, Chennai, Tamil Nadu, India. A copy of the authentication 
certificate is attached inAnnexure. 
Treatment 
 
 The collected plant materials were air dried at room temperature for about 5 days until it 
is free from moisture content. The dried materials were powdered by means of mechanical 
grinder and the resulting product was used for further study. 
 
Plant profile 
The term medicinal plants or herbs have been identified and played a significant role 
from the Stone Age period in maintaining good health and well-being of human. Herbal 
medicine is based on the premise that plants contain natural substances that can promote health 
and alleviate illness. A rich heritage of information and a large body of evidence was available in 
ancient scholastic works in the Indigenous systems of Medicine: Ayurveda, Siddha, Unani and 
Homeopathy drug.   
For more than a decade, the pharmaceutical industry had disproportionate influence on 
the practice of medicine, as well as biomedical research. Meanwhile, the natural medicine has 
increasingly entered the spotlight, and a new study brings more attention to the latter. Herbal 
drugs or medicinal plants, their extracts and their isolated compound(s) have demonstrated 
spectrum of biological activities and continued to be used as medicine in folklore or food 
supplement for various disorders. 
An estimate suggests that about 13, 000 plant species worldwide are known to have use 
as drugs. The trend of using natural products has increased and the active plant extracts are 
frequently used for new drug discoveries and for the presence of active phyto-therapeutic 
materials.  
 
MIMOSA PUDICALINN. 
 
Figure I. Mimosa pudica Linn. 
“Mimic” means to allude and “pudica” means bashful, results the name Mimosa pudica 
to that plant.
1 
In legume family, Mimosa is one of the largest genera which distribute more than 
500 species. Mimosa pudica L. (Mimosaceae) is a common plant in moist waste ground, lawns, 
open plantations and weedy thickets. It is native from Middle America and now widely 
distributed in all tropical areas
[53]
. Mimosa Pudica seeks attention of the researchers worldwide 
for its pharmacological activities such as anti diabetic, antitoxin, anti hepatotoxin, antioxidant 
and wound healing activity. Mimosa pudica Linn locally known as chuimui (Eng: Touch me not) 
in Malwa region, India, is traditionally used as an agent for birth control among rural people. 
This creeping perennial herb has been mentioned as a tribal medicine all over India
[54]
.  
Traditionally M. pudica is used in the treatment of headache, migraine, insomnia, 
diarrhea, dysentery, fever, piles and fistula. Roots in the form of decoction are used to treat 
urinary complaints and in diseases arising from corrupt blood and bile. The paste of the leaves is 
applied to glandular swelling and dressing for sinus. Only few pharmacological studies have 
been reported on leaves of M.pudica like hypoglycemic 
[55]
 and anticonvulsant activity. Leaves 
of this plant has been used to control swelling and dressing of wounds. The claim that the anti-
inflammatory activity of M. pudica leaves is speculative and has not yet been documented. In the 
present study an attempt has been made to evaluate the anti-inflammatory efficacy of M. pudica 
leaves in validated models of rates.  
Botanical Information 
Family: Leguminosae 
 A diffuse under shrub, 50-90 cm high, native of tropical America and naturalized nearly 
throughout topical and sub-tropical parts of India. Stem and rachis clothed with prickles; leaves 
bipinnate: pinnae 2-4, digitatively arranged, with 10 pairs of leaflets; flowers in pinkish globose 
heads; pods small, flat, straw coloured with many bristles; seeds 3-5. 
 
Figure J. Parts of M. pudica 
This is the second biggest family among the dicotyledons (being second only to 
Compositae), and has varying characteristics. As such, it has been divided into the following 
sub-families; Papilionaceae, Caesalpinieae and Mimoseae. The division is primarily based on the 
characteristics of the corolla and stamens. All these sub-families are well represented in 
India.From an economic standpoint, this is one of the most important families. It probably ranks 
second to Gramineae in the order of importance. 
The picture below depicts the following parts: 
A1- Stem with aerial parts 
A2- Androecium 
B1- Flowering top 
B2- Fruit 
B3- Floral diagram 
 
Synonyms: 
Language Vernacular name 
Sanskrit Namaskari 
Ayurveda Lajjalu 
Hindi 
Chui mui 
Lajawanti 
Tamil Tottal sinungi 
Bengali Lojjaboti 
Malayalam Thottavadi 
Marathi Lazalu 
Kannada Muttidare  muni 
Indonesia Putri malu 
 
Myanmar (Burma) Hti ka yoan 
Latin Pudica 
Malaysia Pakok semalu 
European Naa - me – toque 
 
Sensitive 
 
Dormideira 
Spanish Mori – vivi 
 
Active constituents
[56]
 
 Crocetin dimethyl ester and tannin have been isolated from the plant.  
 The mucilage from seed is composed of D-xylose and D-glucoronic acid 4-O-(3, 5-
dihydroxybenzoic acid)-b-D-glucoronide. It has four flavones namely   7, 8, 3‟, 4‟-
tetrahydroxyl-6-C-[alpha-l-rhamnopyranosyl-(1→2)]-b-D-glucopyranosyl flavone (I); 5, 
7, 4‟-trihydroxyl-8-C-[a-l-rhamnopyranosyl-(1→2) ]- D-glucopyranosyl flavone (III) 
and  catcher (IV).   
 A saponin and a bufadienolide were reported in M. pudica seeds.  
 P-Flavanoids, Phenolic constituents, Saponins, Glycosides, Gums, Tubuline, Phytosterol, 
Adrenaline like substances - leaf extract. 
  Green yellow fatty oil -17%, Terpenoids,   Coumarins, Quinines , derivatives of 4-α-(b-
d-glucopyranosyl-6-sulphate) gallic acid , c- glycosylflavone, Phenolic ketone, Jasmonic 
acid, Nor-epinephrine, d-pinitol (3-mono-methyl ether of inositol), b-sitosterol. 
 Coumaric acid is a common plant constituent. Coumaric acid derivatives act as leaf-
opening substances in other nyctinastic plants. C-glycosyl flavones present in aerial part.  
 The leaves contain beta sitosterol and phenolic ketones. Oil extract contains amino acid 
and aminoacid derivatives like N-dl-Alanylglycine, dl-Alanyl-dl- Valine, d-Alanin, dl-
Alanin ethyl ester, dl-Alanyl-dl-Valine and 1-Alanine ethyl amide .oil extact possess 
derivatives of fattyacid like 9, 12-Octadecadienoic acid (Z, Z), methyl ester, 11, 13-
Eicosadienoic acid.  
 The other constituents present in the oil extract are methyl ester, 2-methylamino-N- 
phenyl-acetamide, 1-Octanamine, N-methyl, 1-Butanamine, N-methyl, Meglumine, 2-
methylamino-n-phenyl acetamide, - 1, 3-Dioxolane-4-methanol, 2, 5-Dimethoxy-4-
(methylsulphonyl) amphetamines, 9.12-Octadecadien-1-ol and 11, 13-Eicosadienoic acid, 
methyl ester.
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 The Structures of selected phytochemicals (mimosine, tyrosine 3,4-dihydroxypiridine, 
mimosinamine, mimosinic acid) from Mimosa pudica. 
 
Use of chemical constituents: 
It is reported to contain alkaloid, glycoside, flavonoid and tannins. Its extract immobilizes 
the filariform larvae of Strongyloides stercoralis in less than one hour. In contemporary 
medicine, Mimosa pudica is being investigated for its potential to yield novel chemotherapeutic 
compounds. It contains an alkaloid called mimosine, which has been found to have potent 
antiproliferative and apoptotic effects. Aqueous extracts of the roots of the plant have shown 
significant neutralizing effects on the lethality of the venom of the monocled cobra (Naja 
Kaouthia). It appears to inhibit the myotoxicity and enzyme activity of cobra venom. M. pudica 
contains mimosine which is a toxic alkaloid. Adrenalin like substance has been identified in the 
extract of its leaves. Some workers have reported the presence of Crocetin dimethyl Easter in the 
extract of the plant. Roots contain tannin up to 10 per cent. Seeds contain a mucilage which is 
composed of d-xylose and d-glucuronic acid. The plant extract contains green yellow fatty oil up 
to 17 per cent. The plant is reported to contain tubuline and a new class phytohormone turgorines 
is found to be active in the plant. The periodic leaf movement factors are reportedly the 
derivatives of 4-o-(b-D-glucopyranosyl-6-sulphate) gallic acid. 
Leaflet movement physiology
[57]
 
 Figure K. Drooping leaves of M. Pudica 
The leaflets fold together in the early evening and reopen at sunrise. It is called bashful or 
sensitive because the leaflets fold together on touching, warming and shaking. The phenomenon 
is called seismonastic movement due to a rapid change in turgor pressure and changes in 
membrane permeability in the pulvini cells in the leaf regions with rapid movement of calcium 
ions. At night, the leaves also fold and bend, termed nyctonastic movements (reaction to absence 
of light). Seismonastic Movement / Actin Cystoskeleton: Study showed fragmentation of actin 
filaments occurring during bending was invovled in the regulation of movement. The effect of 
phosphatase inhibitors on the actin cytoskeleton affects dynamic reorganization of actin 
filaments and causes the seismonastic movement.Mimosa pudica is a thigmonastic plant that 
reacts in response to stressors such as electrostimulation, wound, wind, vibration, touch, drought, 
change of illumination, and hot or cold stimuli. Mimosa pudica reacts to stimulation by closure 
of leaves and descent of petiole. The anatomy of M. pudica is unique and contributes to the 
bioelectrochemical response mechanism of the plant. The propagation of action potentials is a 
signaling mechanism in M. pudica. The action potentials that occur in plants have many of the 
same properties as action potentials that occur in animals including the allor-nothing law, 
threshold potential, and refractory period. Tactile stimulation of M. pudica induces transmission 
of an action potential that stops at the base of a single pinna with no further transmission 
occurring, leaving leaflets from neighboring pinnae unfolded.  
 
Applications of M. pudica in Traditional Healthcare System
[58]
 
Ayurveda has declared that its root is bitter, acrid, cooling, vulnerary, alexipharmic, and 
used in the treatment of leprosy, dysentery, vaginal and uterine complaints, inflammations, 
burning sensation, asthma, leucoderma, and fatigue and blood diseases. Unani Healthcare 
System its root is resolvent, alternative, and useful in the treatment of diseases arising from 
blood impurities and bile, bilious fevers, piles, jaundice, and leprosy etc. Decoction of root is 
used with water to gargle to reduce toothache. It is very useful in diarrhea (athisaara), amoebic 
dysentery (raktaatisaara), bleeding piles and urinary infections. It arrests bleeding and fastens the 
wound healing process. It is mainly used in herbal preparations for gynecological disorders. It 
has been said to have medicinal properties to cure skin diseases. It is also used in conditions like 
bronchitis, general weakness and impotence. It is also used to treat neurological problems. The 
content of M. pudica has a capacity of arresting bleeding and it fastens the process of healing of 
wounds. It is recommended in diarrhea, amoebic dysentery and bleeding piles. It is also used in 
herbal preparations of gynecological disorders. Its extract can cure skin diseases. Some herbal 
doctors recommend it for bronchitis, general weakness and impotence. All the five parts of the 
plant (that is the PANCHANG) - leaves, flowers, stems, roots, and fruits are used as medicines in 
the traditional healthcare systems. In India, different parts of the plant have been in popular use 
for treating various ailments since long.  
Recent researches show that the extract of this plant can be used for checking child birth. 
Some authors have reported that this herb can replace contraceptive pills if researches are done 
properly. According to different researches done so far, Mimosa Tenuiflora bark is used to relax 
the mind, and relieve depression, mental distress, irritability, severe palpitations, and amnesia. It 
is a mood enhancer and improves circulation of the blood. Some believe Mimosa can reduce the 
onset of baldness. Due to its ability to promote healthy cell growth, Tepezcohuite is used in 
shampoos, creams, capsules, and soaps. In Ayurvedic and Unani medicine, Mimosa pudica root 
is used to treat bilious fevers, piles, jaundice, leprosy, dysentery, vaginal and uterine complaints, 
inflammations, burning sensation, fatigue, asthma, leucoderma, and blood diseases. In Western 
medicine, Mimosa root is used for treating insomnia, irritability, premenstrual syndrome (PMS), 
menorrhagia, hemorrhoids, skin wounds, and diarrhea. It is also used to treat whooping cough 
and fevers in children, and there is some evidence to suggest that Mimosa is effective in 
relieving the symptoms of rheumatoid arthritis. Its consumption is not recommended to 
pregnant or nursing ladies. Due to these reports, it seems to be best to consult a physician before 
using Mimosa internally. Researches regarding safety in young children or those with severe 
liver or kidney disease have not been found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 GLASSWARE AND CHEMICALS 
 The glassware and the laboratory instruments used for study were of analytical grade 
procured from approved organization. 
 
Chemicals Company Name 
Α-Naphthol Himedia, Mumbai 
Ruthenium red 
Phenolphthalein 
Sulphuric acid 
Sodium hydroxide 
Nitric acid 
Ammonia 
Hydrochloric acid 
Glacial acetic acid 
Merck, Mumbai 
Fehling‟s solution A & B 
Benedict‟s reagent 
Dragendroff‟s reagent 
Wagner‟s reagent 
Mayer‟s reagent 
Hager‟s reagent 
Sigma chemicals, USA 
Copper sulphate 
Lead acetate 
Potassium dichromate 
Magnesium turnings 
Tin metal 
Qualigens Fine chemicals, Mumbai 
Ferric chloride 
Acetic anhydride 
Pyridine 
Glacial acetic acid 
Ninhydrin 
Loba Chemicals, Mumbai 
Toluene 
Sodium nitroprusside 
Thionyl chloride 
Ethyl acetate 
Dimethyl amine 
Acetone 
Fisher inorganic and Aromatic Ltd, 
Chennai 
Ethanol S D Fine Chemical Laboratory, Mumbai 
Methanol 
N-Propanol 
Formic acid 
Cyclohexane 
Acetonitrile 
Chloroform 
 
INSTRUMENTS USED 
Instruments Company name 
Analytical balance Sartorius Ltd. Germany 
Digital ph meter Systronics 
Ultra sonicator Lark Park. Ltd, New Delhi 
Centrifuge 412 LAG Remi instrument Ltd, Mumbai 
IKAT 25 Teflon homogenizer Ultra Turrax Ltd, Germany 
Magnetic stirrer Remi instrument Ltd, Mumbai 
Orbit shaker and incubator Labnet scientific services, Chennai 
Deep Freezer Whirlpool 
Rotavapor Buchi, RE121 
Hot air oven Bionics, Delhi 
Thermostatic water bath Bio Technics, Mumbai 
 
4.3 STUDY ON ORGANOLEPTIC CHARACTERISTICS 
Ash value 
 The residue remaining after incineration is the ash content of the drug which consists of 
inorganic salts, naturally occurring in drug or adhering to it or deliberately added to it as a form 
of adulteration. Ash value is a basis to judge the identity or purity of crude drugs. 
 The percentage of ash in medicinal plant materials is determined by three different 
methods: 
1) Determination of total ash 
2) Determination of acid Insoluble ash 
3) Determination of sulphated ash 
 
Total ash 
 There are two types of ash which remains after igniting the plant material and they are 
physiological ash and non physiological ash. The erstwhile is derived from the plant tissue while 
the hindmost is obtained by igniting the extraneous matter like sand and soil adhering to the 
surface of the plant material. These two values of ash constitutes the total ash value. 
 
Determination of total ash 
About 3 gm of the powdered drug was accurately weighed in a silica crucible which was 
previously dried and weighed. The powdered material was spread to a thin layer in the crucible 
and then ignited gradually by increasing the temperature not exceeding 450
0
C until it is free from 
carbon. Cooled in a desiccator and weighed. 
 
The procedure was repeated to the constant weight and the percentage of the total ash 
was calculated with reference to the air dried drug. The total ash value of whole plant of Mimosa 
pudica (Linn) is recorded in Table No 1. 
 
 
Total ash value of the sample =
𝑍−𝑋
𝑌
𝑋 100 
Where,  
Weight of the empty crucible= Z,  
Weight of the crucible with ash= X,  
Weight of the plant material= Y 
 
Determination of acid insoluble ash 
 The ash obtained from the determination of total ash was boiled with 25ml of dilute 
hydrochloric acid for five minutes. The insoluble matter was collected on an ash-less filter paper 
and washed with hot water. The insoluble ash was transferred into a pre-weighed silica crucible, 
was ignited, cooled and kept in desiccators. The procedure was repeated to get constant weight. 
 
 The percentage of acid insoluble ash was calculated with reference to the air dried drug. 
Acid insoluble ash value of the sample = 
100
𝑌
 𝑋 𝐴 
Where,  
Weight of the residue obtained = A,  
Weight of the plant material= Y 
 
Determination of sulphated ash 
 About 1gm of the powdered drug was weighed accurately in a silica crucible. The 
crucible was heated to redness for 10 minutes, gently at first until the drug was thoroughly 
charred. Allowed to cool in a desiccator and weighed. The crucible was cooled and the residue 
was moistened with 1ml of sulphuric acid, heated gently until the white fumes were no longer 
evolved and ignited at 800
0
c ±25
0
c until all black particles had disappeared. The ignition was 
conducted in a place protected from air currents. The crucible was allowed to cool, few drops of 
sulphuric acid was added and again heated. The ignition was carried out as before, allowed to 
cool and weighed. The operation was repeated until two successive weighing did not differ by 
more than 0.5mg.The percentage of sulphated ash was calculated with reference to the air dried. 
Extractive value 
 The extracts obtained by exhausting crude drugs are indicative of approximate measures 
of their chemical constituents and the percentage of extractable constituents present in a given 
plant material is known as extractive value of the particular plant material. Taking into the 
consideration, the diversity in chemical nature and properties of contents of drugs, various 
solvents such as water and alcohol are used for determination of extractives. Extractive value of 
the sample was determined as the method of WHO. 
𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑣𝑒 𝑣𝑎𝑙𝑢𝑒 % =
𝑊𝑒𝑖𝑔𝑕𝑡 𝑜𝑓 𝑡𝑕𝑒 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑
𝑊𝑒𝑖𝑔𝑕𝑡 𝑜𝑓 𝑡𝑕𝑒 𝑝𝑙𝑎𝑛𝑡 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 𝑡𝑎𝑘𝑒𝑛
x 100 
Water soluble extractive 
 This method is applied to assess the content and percentage of water soluble constituents 
of crude drugs such as tannins, sugars, mucilage and plant acids. 
 
Alcohol soluble extractive 
 This method can be used to determine the presence and amount of alcohol soluble 
constituents such as resins, tannins and alkaloids. 
i. Determination of water soluble extractive  
Macerated about 5 gm of the air dried coarse powder of whole plant of Mimosa pudica 
(Linn) with 100 ml of chloroform water in a glass stoppered volumetric flask for 24 hours, 
shaken frequently for the first 6 hours and allowed to stand for 18 hours. Filtered rapidly, taking 
precautions against loss of the solvent. 25mlof the filtrate was transferred to a tared flat bottomed 
dish and evaporated to dryness. Dried at 105
0
 C for 6 hours, cooled in a desiccator for 30minutes 
and weighed immediately without delay. The percentage of water soluble extractive value was 
calculated with reference to the air dried drug. 
 The water soluble extractive value of the whole plant of Mimosa pudica (Linn) is 
recorded in Table No 2. 
 
ii. Determination of ethanol soluble extractive 
 5gm of the powdered air dried coarse powder of whole plant of Mimosa pudica (Linn) 
was weighed accurately and taken in a glass stoppered volumetric flask. 100ml of 95% 
ethanol was added to the flask and the plant material was macerated for 24 hours, shaking 
intermittently for the first 6 hours. It was then allowed to stand for 18 hours. Thereafter, it 
was filtered rapidly without loss of solvent. Evaporated 25ml of the filtrate to dryness in a 
tared flat bottom shallow dish, dried at 105
0
 C for 6 hours. Cooled in a desiccator for 30 
minutes and immediately weighed. The recorded value of the ethanol soluble extractive value 
of the whole plant of Mimosa pudica (Linn) is mentioned in Table No.2 
 
4.4 PREMILINARY PHYTOCHEMICAL EVALUATION 
Introduction 
The importance of medicinal plant in drug development is known to us and humans have 
used them for different diseases from the beginning of human history. 
 Traditional folk treatment from wild plants has always guided researchers to search for novel 
medications to develop healthy life for humans and animals.  
In addition, some medicinal plants are still obscured within the plant which need to be 
scientifically evaluated. 
Preliminary screening of phytochemicals is a valuable step, in the detection of the bioactive 
principles present in medicinal plants and subsequently may lead to drug discovery and 
development. In the present study, chief phytoconstituents of the medicinal plant was identified 
in order to relate their presence with bioactivity of the plant. 
 
Phytochemical analysis is divided into two categories: 
1. Qualitative 
2. Quantitative 
 
 
 
 
Standard procedures: 
1. Sofowara(1993) 
2. Trease and Evans(1989) 
3. Harborne(1973) 
 
4.5 PREPARATION AND METHOD OF EXTRACTS  
 About 750 grams of powdered whole plant of Mimosa pudica (Linn.) was taken in a 
5000ml of round bottom flask and extracted using cold extraction method for 12 days using 
ethanol (50%) with occasional stirring. The ethanol extract was filtered through Whatman 
filter paper to remove the impurities present. The ethanolic extract was concentrated by 
vacuum distillation, cooled and placed in desiccator to remove the excessive moisture. 
 
Quantity of extract obtained- 154.21 grams from 750 grams of the raw material. 
 Qualitative Phytochemical Screening: 
 The extracts of Mimosa pudica (Linn.) was subjected to the preliminary phytochemical 
analysis using following chemical tests for the identification of various active constituents 
present. 
Following are the tests carried out to identify the possible phytoconstituents and the results are 
tabulated below: 
A. Detection of carbohydrates 
1. Molisch’s Test: To 2 ml of the extract, add 1 ml of α-naplathol solution and 
concentrated sulphuric acid through the sides of test tube. Purple or reddish violet 
colour junction between the two liquids reveals the presence of carbohydrates.  
 
 
2. Fehling’s Test: To 1ml of the extract, add equal quantities of Fehling‟s solution A 
and B. Upon heating, a brick red precipitate indicates the presence of carbohydrates. 
 
3. Benedict’s Test: To 5 ml of Benedict‟s reagent, add 1 ml of extract solution and boil 
for 2 minutes and cool.Formation of a red precipitate shows the presence of 
carbohydrates. 
 
B. Detection of alkaloids 
1. Dragendroff’s  Test: To 1 ml of the extract, add 1 ml Dragendroff‟s reagent. An 
orange red precipitate shows the presence of alkaloids. 
 
2. Wagner’s Test: To 1 ml of the extract, add 2 ml of Wagner‟s reagent. Formation of a 
reddish brown precipitate specifies the presence of alkaloids.  
 
3. Mayer’s Test: To 1 ml of the extract, add 2 ml of Mayer‟s reagent. A dull white or 
creamy precipitate declares the presence of alkaloids. 
 
4. Hager’s Test: To 1 ml of the extract, add 3 ml of Hager‟s reagent. Yellow precipitate 
confirms the presence of alkaloids. 
 
C. Detection of proteins and free amino acids 
 
1. Biuret Test: To 1 ml of the extract, add 1 ml of 40% sodium hydroxide solution and 
2 drops of 1% copper sulphate solution. Formation of violet colour indicates the 
presence of proteins. 
2. Xanthoprotein Test: To 1 ml of the extract add 1 ml of concentrated nitric acid. A 
white precipitate is formed, it is boiled and cooled.Then 20% of sodium hydroxide or 
ammonia is added. Orange colour indicates the presence of aromatic amino acids. 
3. Lead Acetate Test: To 1 ml extract, 1 ml of lead acetate solution is added. Formation 
of dull white precipitate indicates the presence of proteins. 
 
4. Ninhydrin Test: Add two drops of freshly prepared 0.2% ninhydrin reagent to the 
extract solution and heat. Development of blue colour reveals the presence of protein 
peptides or amino acids. 
 
D. Detection of Tannins and Phenolics 
 
1. To 1 ml of the extract, add ferric chloride solution. Formation of a dark blue or 
greenish black colour product shows the presence of tannins. 
 
2. To the extract, add potassium dichromate solution. Formation of a precipitate shows 
the presence of tannins and phenolics. 
 
E. Detection of Flavonoids 
 
1. Shinoda’s Test : To 1 ml of the extract, add magnesium turnings and 1-2 drops of 
concentrated hydrochloric acid. Formationof red colour shows the presence of 
flavonoids. 
 
F. Detection of Triterpenoids 
 
1. Dissolve two or three granules of tin metal in 2 ml thionyl chloride solution.Then add 
1 ml of the extract into the test tube. The formation of a pink colour indicates the 
presence of triterpenoids. 
 
 
 
 
G. Detection of steroids 
 
1. Libermann Burchard Test: Dissolve the extract in 2 ml of chloroform in a dry test 
tube. Add 10 drops of acetic anhydride and 2 drops of concentrated sulphuric acid. 
The solution becomes red, then blue and finally bluish green indicates the presence of 
steroids. 
 
2. Salkowski Test: Dissolve the extract in chloroform and add equal volumes of 
concentrated sulphuric acid. Formation of bluish red to cherry red colour in 
chloroform layer and green fluorescence in the acid layer represents the steroid 
components in the tested extract. 
 
3. Liebermann’s reaction :Mix 3 ml of extract with 3 ml acetic anhydride, heat and 
cool, add few drops of concentrated sulphuric acid, blue colour appears. 
 
H. Detection of Saponins 
 
1. About 1 ml of extract is diluted separately with distilled water to 20 ml and shaken in 
a graduated cylinder for 15 minutes. A 1 cm layer of foam indicates the presence of 
Saponins. 
 
I. Detection of Fixed Oils 
 
1. Spot Test: Press a small quantity of extract between two filter papers. Oil stains on 
paper indicates the presence of Fixed Oils. 
 
2.  Saponification Test: To 1 ml of the extract, add few drops of 0.5 N alcoholic 
potassium hydroxide along with a drop of phenolphthalein. Heat the mixture on a 
water bath for 1 -2 hours. The formation of soap or partial neutralization indicates the 
presence of Fixed Oils.  
J. Detection of glycosides 
 
1. Legal Test: Dissolve the extract in pyridine and add sodium nitroprusside solution to 
make it alkaline. The formation of pink red to red colour shows the presence of 
glycosides. 
 
2.  Baljet Test: To 1 ml of the test extract, add 1 ml sodium picrate solution and 
transformation of yellow to orange colour reveals the presence of glycosides. 
 
3. Borntrager’s Test: To 1 ml of extract solution, add a few ml of dilute sulphuric acid. 
Boil, filter and extract the filtrate with chloroform. The chloroform layer is treated 
with 1 ml of ammonia. The formation of red colour shows the presence of 
Anthraquinone Glycosides. 
 
4.  Keller Kiliani Test: Dissolve the extract in acetic acid containing traces of ferric 
chloride and transfer to a test tube containing sulphuric acid. At the junction, 
formation of a reddish brown colour, which gradually becomes blue, confirms the 
presence of glycosides. 
 K. Detection of gums 
 
1. Hydrolyse the test solution using dilute hydrochloric acid. Perform Fehling‟s or 
Benedict‟s test. Red colour is developed. 
 
L. Detection of mucilage 
1. Powdered drug swells in water. 
2. Powdered drug material shows red colour with ruthenium red. 
 
 
 
4.6 ANALYTICAL METHODS 
Fluorescence analysis 
Fluorescence is the emission of light by the organic substance that has absorbed light or other 
electromagnetic radiation. It is a form of luminescence which occurs frequently in nature in some 
minerals and in various biological states. Fluorescent characteristics of the raw plant powders 
and after treating them with chemical reagents were observed in day light (visible) as well as 
under UV radiation.  
Chromatographic study 
Thin Layer Chromatography (TLC): The TLC identity tests provided in the chromatographs 
include identification of the drug based on its major chemical constituents. 
TLC of Alkaloids 
Preparation of Extracts 
Preparation of mother extract 
 1 gm of 50% ethanolic extract of whole plant of Mimosa pudica (Linn) was dissolved in 
50 ml of 50% ethanol by shaking for 15 minutes at 60
o
 C with 50 ml of 50% ethanol. It was 
filtered through Whatman filter paper, and excess of ethanol was added into the marc. The 
resultant filtrate was made upto 100 ml with 50% ethanol to obtain a concentration of 10mg/ml. 
Preparation of alkaloidal fraction 
 1 gm of 50% ethanolic extract of Mimosa pudica (Linn) (whole plant) was moistened 
with 1ml of 10% ammonia solution and then extracted by shaking for 15 minutes at 60
o
 C with 
5ml of methanol. It was filtered through Whatman filter paper, and excess of methanol was 
added into the marc. The resultant filtrate was made upto 100 ml with methanol to obtain a 
concentration of 10mg/ml. 
 
Preparation of Methanolic fraction 
 1 gm of 50% ethanolic extract of whole plant of Mimosa pudica (Linn) was dissolved in 
50 ml of methanol by shaking for 15 minutes at 60
o
 C with 50 ml of methanol. It was filtered 
through Whatman filter paper, and excess of ethanol was added into the marc. The resultant 
filtrate was made upto 100 ml with methanol to obtain a concentration of 10mg/ml. 
Preparation of ethyl acetate fraction 
 1 gm of 50% ethanolic extract of whole plant of Mimosa pudica (Linn) was dissolved in 
50 ml of ethyl acetate by shaking for 15 minutes at 60
o
 C with 50 ml of ethyl acetate. It was 
filtered through Whatman filter paper, and excess of ethyl acetate was added into the marc. The 
resultant filtrate was made upto 100 ml with ethyl acetate to obtain a concentration of 10 mg/ml. 
Stationary phase – Silica gel GF plate 
Mobile phase 
 Chromatography was tried with the following solvent system. 
a. Toluene-ethyl acetate-dimethyl amine (70:20:10) 
b. Chloroform-dimethyl amine(90:20) 
c. Toluene-acetone-ethanol-Concentrated ammonia (40:40:6:2) 
d. Acetone-water- Concentrated ammonia (90:7:3) 
e. Chloroform-methanol (85:15) 
f. Toluene-methanol (86:14) 
g. N-Propanol-formic acid-water(90:1:9) 
h. Cyclohexane-chloroform-glacial acetic acid(45:45:10) 
i. Acetonitrile-methanol (4:6) 
The solvent system Acetonitrile-methanol gave more satisfactory spot in the ratio 4:6 for 
alkaloid. 
 
Detection of component 
 Visualising agent: Dragendorff reagent 
 Colour of the spot: reddish brown 
Application of the extract 
 All the extract 10 mg/ml was taken in a capillary tube and spotted on the plate keeping a 
distance of about 2 cm above the base of the plate. 
Development of the chromatogram 
 The plates were then developed in TLC chamber previously provided and saturated with 
appropriate solvent system. After the development of the chromatogram, the plates were 
removed treated with visualizing agents and examined for the presence of the different spots. 
The Rf value were calculated and tabulated in Table No 5. 
 
 
 
 
 
 
  
 
 
 
 
V. STUDY PLAN 
5.1 Procurement of animals  
Adult albino female rats of Wistar strain (150-200 g) were collected from C.L. Baid 
Metha college of Pharmacy were used in the pharmacological and toxicological studies. The 
animals were maintained and acclimatized to animal house conditions using paddy husk bedding 
at 25 ± 2
0
C temperature and 50 ± 5% humidity with day night cycle (12 ± 1 h) in solid bottomed 
polypropylene cages. The rats were fed with balanced rodent pellet diet from Poultry Research 
Station, Nandanam, Chennai, India and water ad libitum was provided throughout the 
experimental period. The animals were sheltered for a week and prior to the experiment they 
were acclimatized to laboratory temperature. Food was withdrawn 2 hours before and during 
experimental duration. The protocol was approved by Animal Ethics Committee constituted for 
the purpose as per CPCSEA Guideline. 
TOXICITY STUDIES 
5.2 Acute oral toxicity study  
Acute toxicity studies were conducted in female albino rats (150-200 g) body weight by 
Staircase Method of Ghosh 
[58]
. The Experimental animals were subjected to acute oral toxicity 
studies as per revised OECD Organization of Economic Co-operation and Development 
guidelines (OECD No. 423) and acute class method.  
Principle: 
The acute oral toxicity class method is a stepwise procedure with 3 animals of single sex 
to assess the short term toxicity of test substance. An average of 2-4 steps may be involved to 
decide the acute toxicity of the plant material which depends on the mortality and morbidity 
status of the animals. The procedure is reproducible where usage ofanimals are minimal (Test 
Guidelines 420 and 425). 
 
 
Procedure: 
The animals were segregated into 5 groups containing 6 animals each. The method is 
established on bio metric evaluation with fixed doses (5, 100, 500, 2000 mg/kg P.O) to enable a 
substance to be ranked for classification purposes according to Globally Harmonized System 
(GHS) which causes acute toxicity.  
The animals were fasted over-night prior to dosing (provided only water). Following the 
period of fasting, the animals should be weighed and the ethanolic extracts of Mimosa pudica 
(Linn.) was administered to the groups orally by gastric intubation canula. Single oral dose of the 
plant extract were devoid of any toxicity up to 2000 mg/kg body weight in albino rats for 14 
days. The animals were observed at an hourly basis for 24 hours to assess the behavioral 
changes, locomotion, convulsions and mortality.  
If mortality was observed in 5 or 6 animals among 6 animals, then the dose administered 
was assigned as a toxic dose. If mortality was observed in 3 animals, then the same dose was 
repeated again to confirm the toxic dose.  
The optimum conditions for experiments were decided on the basis of pilot experiments 
carried out using five animals per group. 200 mg/kg (P.O) and 400 mg/kg (P.O) was taken as the 
therapeutic oral dose (low and high dose) for the compound. 
Animals were weighed before and after the acute toxicity experimental studies. The 
following clinical observations of the animals were observed and recorded: 
 Toxic signs 
 Changes in body weight 
 Cage-side observations 
o Feces colour  
o Skin and fur colour 
o Eyes and mucous membrane 
o Biting 
o Arousal 
 Physical examination 
o Cardiovascular system 
 Heart rate 
o Autonomic nervous system 
 Lacrimation 
 Salivation 
 Fecal boluses 
 Urinary incontinence 
o Central nervous system 
 Tremors 
 Convulsions 
 Vocalization 
 Motor activity level 
 Rearing 
 Gait description 
 Response 
 Click response 
 Approach response 
 Touch response 
 Tail pinch response 
 Reflux 
 Flexor reflux 
 Extensor reflex 
 Pinna reflex 
 Pupillary reflex 
 Body posture 
 Fore limb hoping 
 Hind limb extension 
 Surface righting reaction 
 Aerial righting reaction 
 Proprioceptive reaction 
 
5.3 INVIVO ANTI-ARTHRITIC STUDY 
Chemicals 
 Freund‟s complete adjuvant (Sigma Aldrich) and all other chemicals and reagents used 
for the study were of analytical grade procured from approved organization. 
Animals 
 Female Wistar rats of body weight 150–200 g were used for the study. The animals were 
maintained under standard environmental conditions and were fed with standard pellet diet and 
water ad libitum. All the experimental procedures were carried out in accordance with 
Committee for the Purpose of Control and Supervision of Experiments on Animal (CPCSEA) 
guidelines and all the experimental procedures were approved by IAEC/L/02/CLBMCP/2017 
(Approval no.). 
Induction of arthritis 
 To induce arthritis, animals were first anesthetized with a small amount of ether vapor, 
then a single injection of 0.2 ml Complete Freund‟s adjuvant dissolved in mineral oil (sterile) 
was injected delicately into the sub-plantar region of  hind paw. 
Treatment regimen 
The anti–arthritic activity was performed according to Jubie et al. [59] method. After 
classifying and grouping animals according to their weight, each animal was marked and placed 
in a cage with a letter identifying the cage. 
 The animals were divided into five groups of six animals each. Each group was given a 
dose schedule as follows:  
1. Group I -Vehicle control, 1%  w/v DMSO, p.o; (nonarthritic); 
2. Group II - Negative control (0.1ml Complete Freund‟s adjuvant); 
3. Group III -Arthritic animals treated with standard, 0.75 mg/kg Methotrexate, p.o; 
4. Group IV - Arthritic animals treated with 200 mg/kg of Mimosa pudica(Linn.), p.o; 
5. Group V -Arthritic animals treated with 400 mg/kg of Mimosa pudica(Linn.), p.o; 
Vehicle control animals were given 1% w/v of DMSO solution daily. 
Negative control group was given a single injection of 0.2 ml Complete Freund‟s adjuvant in 
mineral oil into the sub-plantar region of hind paw on day 1 under light ether anesthesia.  
The stock solution was prepared on a daily basis for the treatment of low dose, high dose and 
standard dose animals depending upon the body weight of animals. The plant extract was diluted 
in DMSO because of its solubilizing effect and no solubility in water. Freshly prepared drug was 
introduced into the group of animals through oral administration using oral cannula. 
The drug treatment was continued with the respective groups for 40 days.   
Every day animals were carefully and thoroughly inspected by examining the affected paw 
and animal‟s general status. The health status parameter included paw volume, animal body 
weight, arthritic score and behavioural observations such as locomotor activity. The body 
weights of all the animals were recorded in grams on weekly basis by using single pan weighing 
balance. Body movement was measured by observing the time taken by individual animal to 
move two meter distance and statistical analysis is performed. The animals were sacrificed on 
day 41 to study the histology of the joint. 
PARAMETERS: 
1. Paw edema volume 
Requirement:- 
Plethysmometer 
Mercury 
Marker 
 Figure L. Plethysmometer 
Procedure:- 
Mercury Plethysmometer should be filled with mercury to a designated level. A mark 
was made on both the legs at lateral malleolus to facilitate uniform dipping and recording of paw 
volumes. The animal‟s paw was dipped into one column and the displacement of mercury was 
noted when the paw was dipped in mercury column up to a predetermined mark on the paw. The 
difference in paw volume indicates the degree of inflammation.  
 
Evaluation:- 
The hind paw volumes of all the animals were measured just before Freund‟s complete 
adjuvant injection on day 0 and thereafter at different time intervals (day 4, 13, 25, 40) using a 
plethysmometer instrument [12, 13 & 14]. The paw volume changes were calculated by 
subtracting initial paw volumes from the final paw volumes. 
Paw volume =
 𝑉𝑐−𝑉𝑜 −(𝑉𝑖−𝑉𝑜)
 𝑉𝑐−𝑉𝑜 
 x 100 
Where,  
Vc = Paw volume after induction 
Vo = Paw volume before induction 
Vi= Paw volume after treatment 
 
2. Arthritic score 
Visual observation:- 
The degree of arthritis was continuously monitored on day 0, 4, 13, 25 and 40 after 
injection of Freund‟s adjuvant. The arthritic score was monitored by set visual criteria and 
changes in the morphological feature of the arthritis like redness, swelling and erythema was 
noted and scoring was done.
[60,61]
 
3. Locomotor activity 
Instrument:- 
Slab (Animal to travel a two meter distance) 
Procedure:- 
The locomotor activity of rats were recorded individually for each animal. Body 
movement was measured by observing the time taken by individual animal to move a certain 
distance. It was recorded on day 0, 4, 13, 25, 40 of the experiment. 
Evaluation:- 
 The locomotor activity of an individual animal was measured and recorded. 
4. Body weight 
Apparatus:- 
Weighing balance 
Procedure:- 
 Measuring balance was calibrated and the mark was kept at zero. Each animal was placed 
in thebalance and the weight was recorded. 
Evaluation:- 
 Body weight was recorded at different time intervals (day 0, 4, 13, 25, 40).Changes in 
body weight was calculated. 
5.4 INVITRO ANTI-ARTHRITIC STUDY 
1. Biochemical estimations 
 On day 41, after anesthesia(using ether vapor), cardiac puncture was done and a 
centrifuge tube was introduced to withdraw blood. Blood with and without anticoagulant was 
centrifuged for 15 min (3000 rpm) and the plasma and serum was collected. Total proteins such 
as albumin and globulin, Rheumatoid factor(Rf) and C-Reactive protein(CRP) levels were 
quantified.  
 
Estimation of total protein: 
 Spectrophotometric method using erythrosine B dye was carried out for the determination 
of total proteins in blood plasma from rats. 
 
Materials and reagents: 
Bovine serum albumin (BSA-Sigma) solutions 
3',3",5',5"-tetrabromophenolphthalein ethyl ester(TBPEE) 
Ultraviolet and visible spectrophotometer 
Procedure: 
A 50 µl aliquot of blood plasma was transferred to a test tube and the volume was made 
up to 2.0 ml with distilled water. A 50 µl aliquot of this solution was transferred to a 
second test tube and the volume was adjusted to 2.0 ml with 0.2 mol L
-1 
of acetic acid. 
Standard curve was prepared by taking 0.0, 20.0, 40.0, 60.0, 80.0, 100.0 and 120.0 µl of 
standard solution of BSA (1.5 g L
-1
), a calibration curve with the concentrations from 0.0 
to 84.0 µg mL
-1 
was obtained, the volumes were adjusted to 2.0 ml with acetic acid (0.2 
mol L
-1
). After, in all tubes, 100 µl of TBPEE (0.005% m/v) was added, shaken and 
incubated at 37ºC for 10 minutes. The tubes were then cooled to room temperature and, 
after 30 minutes the absorbances at 610 nm were read against the blank (0.0 µg mL
-1
). 
 
 
 
2. Protein Denaturation Inhibition Study 
Principle: 
 Denaturation is caused by the application of an external stress such as heat or by 
introducing chemical compounds such as strong acid or base, concentrated inorganic salt, an 
organic solvent. Proteins lose their tertiary structure and secondary structure thereby their 
biological function is lost. Protein denaturation is a well documented cause of inflammation. 
Requirements: 
 Bovine serum albumin (5% w/w aqueous solution) 
 Plant extract 
 Polyethylene glycol 
 Phosphate buffer saline(pH 6.3)  
Procedure: 
 The method of protein denaturation was conducted as per the method described by 
Mizushima and Kobayashi [62]. The reaction mixture consisted of0.45 ml of bovine serum 
albumin (5% w/w aqueous solution) and 0.05ml of ethanolic extracts of Mimosa 
pudica(Linn.) at variable concentrations ranging from 100 to 1000 µg in 10% v/v of 
polyethylene glycol. The pH adjustment was doneto 6.3 by adding 0.1N HCl and the samples 
were incubated at 37
0C for 20 min and then heated at 57˚C for 3min. After cooling the 
samples, 2.5 ml phosphate buffer saline (pH 6.3) was added to each tube. The resulting 
turbidity was measured at 660 nm spectrophotometrically. For control tests, 0.05 ml distilled 
water was used instead of plant extracts while product control tests lacked bovine serum 
albumin. The percentage inhibition of protein denaturation was calculated as follows. The 
control represents 100% protein denaturation. The results were compared with acetyl 
salicylic acid(positive control) in the present investigation. 
Percent Inhibition = 100 -
(𝑂.𝐷 𝑜𝑓  𝑡𝑒𝑠𝑡−𝑂.𝐷 𝑜𝑓  𝑝𝑟𝑜𝑑𝑢𝑐𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙 )
𝑂.𝐷 𝑜𝑓  𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 x 100 
 
3. Proteinase Inhibition Study  
Principle: 
 Proteinase inhibitors play a major role in protecting the tissue against damage which is 
caused by proteinases and it has been implicated in the arthritic reactions. Neutral serine 
proteinases are present in the lysosomal granules of neutrophils which is considered to be a rich 
source of proteinases. 
Requirements: 
 Trypsin 
 Tris–Hydrochloric acid buffer (pH 7.4) 
 Casein 
 Perchloric acid 
Procedure: 
 The proteinase enzyme inhibitory assay was studied by the method described by Oyedapo 
et al. 
[63]
. The reaction mixture contained 0.06 mg trypsin, 1.0 ml of 25 mM Tris–Hydrochloric 
acid buffer (pH 7.4) and 1.0 ml of ethanolic extracts of Mimosa pudica(Linn.) at variable 
concentrations ranging from 100 to 1000 µg in polyethylene glycol. The mixtures were 
incubated at 37
0
 C for 5 minutes and then 1.0 ml of 0.8% (w/v) casein was added. The mixtures 
were incubated for additional 20 minutes and 2.0 ml of 70% (v/v) perchloric acid was added to 
terminate the reaction. The cloudy suspension was centrifuged and absorbance of the supernatant 
was read at 280 nm against buffer as blank. The percentage of inhibition was calculated. The 
results were compared with acetyl salicylic acid (250 µg/ml) treated samples. 
Percent inhibition = 100 -
 𝑂.𝐷 𝑜𝑓  𝑡𝑒𝑠𝑡  −𝑂.𝐷 𝑜𝑓  𝑝𝑟𝑜𝑑𝑢𝑐𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙  
𝑂.𝐷 𝑜𝑓  𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 X 100 
 
 
 
OTHER METHODS 
1. Histological analysis of ankle joints 
 The animals were sacrificed on day 41, the ankle joints were removed and preserved in 
10% buffered formalin for 24 hours. It was followed by decalcification in 5% formic acid, 
processed for paraffin embedding sectioned at 50 µm thickness. The sections were stained with 
hematoxylin and eosin H & E 
[64]
 and evaluated under light microscope for the presence of 
hyperplasia of synovium, pannus formation and destruction of joint space. 
2. X-ray radiography 
Rats were anaesthetized by intraperitoneal injection of 50mg/kg pentobarbitone sodium 
on day 41. Radiographs were taken with X-ray apparatus for lateral and mediolateral projection. 
The severity of the joint and bone deformation was blindly scored according to the extent of 
osteoporosis, joint spaces, osteophytes and joint structure 
[65,66]
 on a scale of 0-4  
0 -No degenerative joint changes,  
1. Slight soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, 
subluxation, and degenerative joint changes,  
2. Low to moderate soft tissue volume, joint space, subchondral erosion, periostitis, 
osteolysis,   
3. Pronounced soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, 
subluxation, and degenerative joint changes,  
4. Excess soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, 
subluxation, and degenerative joint changes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
The data was analyzed in terms of Mean ± Standard error of Mean (SEM). For statistical 
analysis, multiple comparisons of data were made using one and two way analysis of variance 
(ANOVA) followed by Dunnet‟s test was used for post hoc analysis. Significance was 
statistically acceptable at a level of P < 0.05. Software program GraphPad Prism was used for all 
data analysis.
[67]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI. RESULTS 
Acute toxicity results: 
No toxic symptoms were observed after administration of different dose levels of extract 
up to maximum of 2000mg/kg p.o. according to OECD guideline 423; and in addition the higher 
dose of 2000mg/kg dose was administered to a group of animals. No symptoms or adverse 
events were identified. Hence, safe tolerable dose was used as therapeutic dose for further 
pharmacological study. From this experiment, the minimum and maximum therapeutic dose 
level of EMP extracts were studied as 200mg/kg and 400 mg/kg. 
 
Invivo results 
1. Paw edema volume 
In FCA induced arthritis model, rats developed a chronic swelling in multiple joints with 
the influence of inflammatory cells, erosion of joint cartilage, bone destruction and remodeling. 
These inflammatory changes ultimately result in the complete destruction of joint integrity and 
functions in the affected animal
[68]
. 
The extract of Mimosa pudicaLinn.at 400 mg/kg inhibited rat paw edema which is 
comparable with standard drug methotrexate at40
th
 day. The results of which are shown in Table 
6 . The determination of rat paw swelling is apparently simple, sensitive and one of the quick 
procedures for evaluating the degree of inflammation and the therapeutic effects of drugs. The 
chronic inflammation involves the release of number of mediators like cytokines, GM-CSF, 
interferons and PGDF. These mediators are responsible for pain and destruction of bone, 
cartilage that can leads to severe disability.  
 
2. Arthritic score 
Picture 1 depicts the scoring of arthritis by set visual observation of the respective groups 
of animals after drug treatment and the results are as follows:  
 
 
 
Group 1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
 
 
Normal paw with no macroscopic 
sign of arthritis 
Group 2 
 
 
Negative control 
 
 
Gross deformity and inability to use the limb 
since multiple joints were inflamed and 
erythema progressively increased 
 
Group 3 
 
 
Standard, Methotrexate 
 
 
Swelling and redness of joint is more when 
compared to the high dose of the extract 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
3. Locomotor activity and body weight 
As the incidence and severity of arthritis increased, there were changes in the body 
weights of the rats during the course of the experimental period. The loss of the body weight 
during arthritic condition was also supported by earlier observations
[69]
, on alterations in the 
metabolic activities of diseased rats.  
The body weight in standard group almost remained same during 40 days of study. In the 
low dose and high dose(200 mg/kg and 400 mg/kg) group of animals, body weight declined after 
9 days of study and significant loss of weight was observed on 18
th
 and 25
th
 day. Methotrexate 
treatment did not produce any significant change in body weight. In non-treated group of rats, no 
significant change in behaviour was observed. During 9
th
 and 18
th
 day of study significant 
decrease in the movement of rats were noted both in plant extract and standard. However, on 40
th
 
Group 4 
 
 
LDMP 
 
 
Moderate swelling and erythema of two              
joints after drug treatment 
 
Group 5 
 
 
HDMP 
 
 
Reduced swelling and erythema of joints after 
drug treatment 
 
day of study restoration of the normal movement was observed when compared with non-treated 
groups. The results of which are shown in table 7. 
 
Invitro results 
1. Effect of M. Pudica extracts on Biochemical parameters 
The results in Table 8 shows that, in untreated animals (negative control group), serum 
levels of CRP and Rfsignificantly increased (P < 0.001) and total protein level significantly 
decreased (P < 0.001) compared to the parameters of animals of the healthy group. In animals 
treated with extracts or methotrexate, all biochemical parameters evaluated tend to return to 
normal values. 
2. Protein Denaturation Inhibition Study 
Anti–arthritic effect of EMP extractwas studied significantly by testing various in–vitro 
parameters. Table 9 depicts the inhibition of protein denaturation of different extracts. In the 
present investigation, all the three extracts inhibited the protein denaturation in a dose dependent 
manner. However, the EMP has got a higher inhibitory percentage of protein denaturation when 
compared (p>0.05) to thepositive control. At the concentrations of 400, 500, 800 and 1000µg/ml, 
the inhibitory percentage of EMP was significantly comparable to the positive control Acetyl 
salicylic acid used in this present investigation. 
3. Protease Inhibition Study  
The proteinase inhibitory activity of the EMP extracts were shown in Table 10. Both the 
EMP extract and the positive control acetyl salicylic acid exhibited a dose dependent anti–
proteinase activity. At concentration of 800 µg/ml the EMP exhibited higher anti–proteinase 
activity of 75.18% when comparable (p>0.05) to the positive control which showed 73.69% of 
anti–proteinase activity at the same concentration. But at the maximum concentration of 
1000µg/ml EMP showed 82.96% protease inhibition against the positive control acetyl salicylic 
acid which showed the inhibition of 85.90% at the same concentration. 
Other methods results: 
Analysis of histopathology of ankle joints 
Histopathology of the ankle joint of healthy control rats revealed no inflammation, a few 
lymphocytes infiltration and no bone necrosis. A massive influx of inflammatory cells, cartilage 
destruction, proliferation of granulation tissue, lymphocytes infiltration and chronic 
inflammation was detected in arthritic control. In contrast to these pathological changes, animals 
having received ethanolic extracts of M. Pudica  or indomethacin showed significant protection 
against necrosis of bones with low influx of inflammatory cells and minimal bone damage 
compared. 
Histopathological analysis of ankle joints stained with H&E 
Group 1 
 Bone and cartilage between the jointsappeared normal.Synoviocytes surrounding 
the cartilage appeared normal 
 No pannus formation and no inflammatory cells infiltration noticed 
Group 2 
 Severe pannus formation (chronic arthritis) surrounding the joints in which extensive 
proliferation of fibro vascular tissueor granulation tissue. 
 Extensive accumulation of synovial fluids noticed in between pannus formation  
Group 3 
 Moderate pannus formation in which proliferation of fibro vascular tissue or granulation 
tissue.  
 Also accumulation of synovial fluids in between pannus formation. 
Group 4 
 Bone structure appeared normal; no erosion noticed  
 Cartilage/ synovialmembranes appeared normal  
 Mild erosion noticed in the cartilage  
Group 5 
 Bone and cartilage surrounding the joints appeared normal  
 Mild pannus formation in which proliferation of fibrous tissue noticed from the cartilage. 
X-ray radiology of hind paws  
Group 1 
 Uninjected control group with no degenerative joint changes    
Group 2 
 Excess soft tissue volume, joint space, sub-chondral erosion, periostitis, osteolysis, 
subluxation, and degenerative joint changes  
Group 3 
 Moderate soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, 
subluxation, and degenerative joint changes. 
Group 4 
 Pronounced soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, 
subluxation, and degenerative joint changes. 
Group 5 
 Low to moderate soft tissue volume, joint space, subchondral erosion, periostitis, 
osteolysis,  subluxation, and degenerative joint changes. 
 
 
 
 
 
 
 
TABLES, GRAPHS AND FIGURES: 
Table No. 1 
Ash values of whole plant of Mimosa pudica Linn. 
 
S. No Type of ash Percentage (W/W) 
1. Total Ash 5.257% w/w 
2. Acid Insoluble Ash 1.611% w/w 
3. Sulphated Ash 7.993% w/w 
 
 
 
Table No. 2 
Extractive values of whole plant of Mimosa pudica Linn. 
 
S. No Type of extractive value Percentage 
1. Ethanol 23.758% w/w 
2. Water 18.964% w/w 
 
 
 
 
 
 
 
Table No. 3 
Nature of phytoconstituents present in the whole plant of Mimosa pudica Linn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(+)Indicates the presence of chemical constituents, 
(-)Indicates the absence of chemical constituents 
 
 
 
 
 
 
 
 
 
 
 
 
Phytoconstituents Observation 
Carbohydrates + 
Alkaloids + 
Proteins & Amino acids + 
Tannins & Phenolics + 
Flavonoids + 
Triterpenoids - 
Saponins + 
Fixed oils + 
Glycosides - 
Gums - 
Mucilage + 
Table No. 4 
Fluorescence analysis of the raw material and whole plant extract of Mimosa pudica Linn. 
 
Sample  Reagent used Visible UV 
Mimosa pudica 
(Linn.)raw 
powder 
(Whole plant) 
1.  1(N) NaOH Yellowish green Green 
2.  1(N) NaOH in Alcohol Yellowish green Green 
3.  1(N) HCI Light brown Green 
4.  50% HNO3 Orange Green 
50% ethanolic 
extract of 
Mimosa pudica 
(Linn.)(Whole 
plant) 
1.  1(N) NaOH Yellowish brown Green 
2.  1(N) NaOH in Alcohol Yellowish brown Green 
 
3.  1(N) HCI Light brown Green 
4.  50% HNO3 Orange Green 
 
Table No 5 
Rf values of the TLC studies on the ethanolic extract of Mimosa Pudica Linn 
 
S. No Extract(10 mg/ml) Solvent System TLC study for Rf 
values 
1. Mother extract  
 
Acetonitrile : 
methanol (8:2) 
Alkaloid 0.54 
2. Alkaloidal fraction Acetonitrile : 
methanol (8:2) 
Alkaloid 0.51 
0.80 
3. Methanolic fraction Acetonitrile : 
methanol (8:2) 
Alkaloid 0.56 
 
4. Ethyl acetate fraction Acetonitrile : 
methanol (8:2) 
Alkaloid - 
 
 
 
Table No 6 
EFFECT OF MIMOSA PUDICA LINN EXTRACTS ON CHANGES IN PAW VOLUME 
INCFA INDUCED ARTHRITIS IN RATS 
 
Paw edema volume 
Group 0
th
 day 9th day 18th day 25th day 40th day 
Control 0.65 ± 0.01 0.66 ± 0.01 0.65 ± 0.02 0.67 ± 0.01 0.67 ± 0.02 
Negative 
control 
0.66 ± 0.02 0.75 ± 0.01 0.80 ± 0.01 0.86 ± 0.02 0.91 ± 0.02 
Standard 0.59 ± 0.01 0.48 ± 0.01 0.43 ± 0.02 0.40 ± 0.01 0.35 ± 0.02 
200 mg/kg 
MP 
0.62 ± 0.02 0.51 ± 0.01 0.42 ± 0.02 0.40 ± 0.01 0.38 ± 0.01
*
 
400 mg/kg 
MP 
0.58 ± 0.02 0.42 ± 0.01 0.36 ±0.01
*
 0.32 ±0.01
**
 0.27 ± 0.01
* 
Values are expressed in mean ± SEM, n = 6, *p<0.05 are significant compared to standard, 
LDMP(200 mg/kg); HDMP(400 mg/kg) 
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Graph I 
 
Table No 7 
Effect of ethanolic extracts of LDMP and HDMP on CFA induced arthritic rats showing 
changes in body weight and locomotor activity 
Group 
Physical and behavioural changes 
0
th
 day 9
th
 day 18
th
 day 25
th
 day 40
th
 day 
BW 
(gms) 
M 
(sec) 
BW 
(gms) 
M 
(sec) 
BW 
(gms) 
M 
(sec) 
BW 
(gms) 
M 
(sec) 
BW 
(gms) 
M 
(sec) 
Control 180±0.02 20 175±0.01 22 170±0.01 24 173±0.02 22 174±0.01 23 
Negative 
control 
170±0.01 20 160±0.01 30 150±0.02 35 100±0.02 50 92±0.02 55 
Standard 170±0.01 20 160±0.02 30 140±0.01 32 130±0.01 32 175±0.01 25 
LDMP 160±0.02 20 150±0.02 30 140±0.02 30 120±0.01 40 100±0.01 40 
HDMP 200±0.02 20 180±0.02 25 160±0.02 25 165±0.01 30 195±0.01* 25 
Values are expressed in mean ± SEM, n =6 ,*p ˂ 0.05 are considered significant compared to 
standard. LDMP(200 mg/kg); HDMP(400 mg/kg); BW – Body weight; M - Movement 
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Graph II 
Table No 8 
Effect of ethanolic extracts of LDMP and HDMP on serum parameters in  
CFA induced arthritic rats 
Group CRP (mg/l) Rf (IU/ml) Total Protein (g/dl) 
Control 1.65 ± 0.01 - 8.0 ± 0.54 
Negative control 6.92 ± 0.22
**
 58.01 ± 1.50 5.4 ± 0.15
*
 
Standard 3.68 ± 0.30
**# 
39.15 ± 0.23
# 
7.6 ± 0.42
* 
LDMP 4.12 ± 0.18
**#
 40.03 ± 0.02
# 
7.1 ± 0.43 
HDMP 3.05 ± 0.05
*#
 36.01 ± 1.51
# 
7.8 ± 0.25
# 
Each value represents the mean ± SEM for ANOVA, n=6, *p<0.05, **p<0.001 when compared 
to healthy control ,
#
p<0.001 when compared to negative control. 
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Table No 9 
Protein Denaturation Inhibition Study 
Concentration 
(mg/ml) 
Inhibitory 
activity of EMP 
Inhibitory effect of  
Acetyl Salicylic Acid 
(%) 
100 24.46 ± 1.12 24.45 ± 1.70 
200 33.62 ± 3.08 32.14 ± 2.21 
400 45.76 ± 1.98 41.77 ± 1.52 
500 54.35 ± 2.37 45.33 ± 2.18 
800 76.48 ± 1.92 69.71 ± 2.43
*
 
1000 87.65 ± 3.01 85.17 ± 2.13* 
Values are expressed in mean ± SD(n=6 ), *p<0.05. Statistical significant test for comparison 
was done by ANOVA followed by Dunnet‟s „t‟ test. Comparison between acetyl salicylic acid vs 
EMP 
% Inhibition of EMP on protein denaturation
Inhibitory activity(%)
EMP(%) Acetyl salicylic acid (%)
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Table No 10 
Protease Inhibition Study 
Concentration (mg/ml) 
Inhibitory activity of 
EMP 
Inhibitory activity of Acetyl 
salicylic acid (%) 
100 21.33 ± 2.18 21.88 ± 1.90 
200 24.21 ± 2.00 27.21 ± 2.31 
400 38.75 ± 3.12 41.75 ± 1.59 
500 45.28 ± 1.65
*
 46.70 ± 2.58 
800 75.18 ± 1.32
*
 73.69 ± 1.25 
1000 82.96 ± 1.72 85.90 ± 1.10 
Values are expressed in mean ± SD(n=6 ), *p<0.05. Statistical significant test for comparison 
was done by ANOVA followed by Dunnet‟s „t‟ test. Comparison between acetyl salicylic acid vs 
EMP 
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VII. DISCUSSION 
Rheumatoid arthritis is an inflammatory, autoimmune disorder which destroys it‟s own 
immune system. The immunologically mediated Complete Freund‟s adjuvant induced arthritic 
model of chronic inflammation is considered as the best available experimental model of 
rheumatoid arthritis
[70]
.Complete Freund‟s adjuvant-induced arthritis is a model 
of chronic polyarthritis with features that resemble rheumatoid arthritis. 
 
In Complete freund‟s adjuvant-induced arthritis model, rats developed a chronic swelling 
in multiple joints with influence of inflammatory cells, erosion of joint cartilage and bone 
destruction and remodeling which have close similarities to human rheumatoid disease. These 
inflammatory changes ultimately result in the complete destruction of joint integrity and 
functions in the affected animal. Also, the Complete Freund‟s adjuvant administered rats showed 
soft tissue swelling around the ankle joints during the development of arthritis, which was 
considered as edema of the particular tissues.  
 
Paw swelling is an index of measuring the anti-arthritic activity of Mimosa pudica 
Linn.at the dose level 200&400 mg/kg, p.o. Mimosa pudica administered groups showed marked 
reduction in paw volume when compared with the Negative control group (Group II). It was also 
found that there was significant weight loss when compared to standard
[71]
. The result of the 
present study also indicates that there is a close relationship between the extent of inflammation, 
loss of body weight and arthritic index. The arthritic scoring was done on the basis of visual 
observation where it can be seen that there is a marked reduction in the swelling and joint 
damage of the drug treated groups
[72]
. It was also noted that the high dose Mimosa pudica Linn. 
Extract proved its efficacy to reduce the inflammation of the paws. The locomotor activity of the 
animals were improved in Group 5 animals(HDMP) when compared to the standard animals. 
 
Assessment of the levels of serum parameters provides an excellent and simple tool to 
measure the anti-arthritic activity of the target drug. The total protein such as albumin and 
globulin was comparatively equal in all the three groups such as control, plant extract and 
standard
[73]
. TheC-Reactive protein levels of the plant extract and standard was marginally equal 
but higher than the control values. Rheumatoid factors are proteins produced by our immune 
system that can attack our own healthy cells of the body. When the levels rise, it might relate to 
some form of auto immune diseases. The Rf value of the high dose plant extract was excellent 
when compared to that standard.  
 
Histopathology provides a noticeable morphological distinctiveness as a practical and 
unambiguous pathognomonic sign of Rheumatoid arthritis. The histopathological analysis 
identified the ability of the bones to re-form upon treatment with Mimosa pudica Linn. Bone 
structures re-calcified upon treatment with the Mimosa pudica Linn.dose dependently. The high 
dose of the plant extract exhibited good therapeutic potential from the study results and is 
therefore consistent with earlier findings that the ability of a drug to suppress inflammation, 
synovitis and protect a joint is desired in rheumatoid arthritis therapy. 
 
Radiographic changes in Rheumatoid arthritis conditions are useful diagnostic measures 
which indicate the severity of the disease. Soft tissue swelling is the earlier radiographic sign, 
whereas prominent radiographic changes like bony erosions and narrowing of joint spaces can be 
observed only in the developed stages (final stages) of arthritis
[74]
. The radiographic features of 
the rat joints in adjuvant induced arthritic model are shown in Picture 3. In Freund‟s adjuvant 
induced arthritic rat (group II), soft tissue swelling along with narrowing of the joint spaces was 
severe which implies the bony destruction in arthritic condition. The standard drug Methotrexate 
(0.75 mg/kg) treated groups have prevented this bony destruction and also there is moderate 
swelling of the joint. Similarly, according to histopathological studies, extracts of Mimosa 
pudica Linn.have shown significant prevention against bony destruction by showing less soft 
tissue swelling and narrowing of joint spaces in the 40 days of treatment when compared with 
Complete Freund‟s adjuvant (Negative control group). 
 
 
 
VIII. SUMMARY 
Indian sub-continent is a rich source of plant & animal wealth which is due to its varied 
geographical and agro climate regions. It is a well known fact that traditional system of 
medicines always played important role in meeting the global health care needs. Arthritis is one 
of the most common auto-immune inflammatory disorders, foremost cause of disability in 
western and developing countries. The presently available synthetic drugs in the market are not 
only economical exploitation but also associated with adverse effects. The synthetic drugs 
includes NSAIDS and DMARDS like Cyclophosphamide, intramuscular gold, sulfasalazine had 
the side effects of stomach ulcers, GIT bleeding, kidney, liver damage and hypertension. The 
given plant Mimosa pudica Linn.provides essential compounds with active principles, having no 
or minimum side effects holds prospect in future rheumatoid arthritis treatment. From the above 
review it should be manifest that there are many medicinal plants which exert anti-arthritic 
activity at a particular dose. 
The preliminary phytochemical studies discovered the presence of various 
phytoconstituents. 
Invivo study was performed with parameters such as paw edema volume, physical and 
behavioural changes and arthritic index and the extract possessed a significant effect on the 
inflammation and joint destruction. 
The biochemical analysis were assessed by estimating the serum values which provided 
favourable effects. 
Invitro study showed the effect of the plant extract on the percentage inhibition of protein 
denaturation and protease enzymes which gave marked responses. 
Other methods such as histopathology and the radiographic X-ray analysis of the groups 
showed good results. 
 
 
 
CONCLUSION 
In conclusion, this study has verified that constituents of the plant suppressed the joint 
inflammation and destruction in adjuvant arthritic rats. We are confident that our data provide 
mechanistic evidence for anti-arthritic appliance of the plant as a promising candidate for 
novel therapeutic agent of Rheumatoid arthritis. 
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